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Abstract 
Cyclic guanidines are an interesting class of molecules that show a wide range of interesting 
biological activity, including cytotoxicity, antimicrobial activity, and antibiotic activity. 
Unfortunately, many of these molecules are isolated from sources that are difficult to obtain, such 
as marine sponges, making acquiring large quantities of these compounds difficult. Existing 
methodology for fashioning this moiety does not allow for the facile construction of analogues. To 
address this limitation, the research in this thesis is dedicated to the development of creating 
structurally complex cyclic guanidines from easily obtainable acylic guanidine substrates. This 
research also aims to create these structures in a manner that is amenable to rapid analogue 
generation. 
In all, this dissertation focuses on Pd-catalyzed carboamination reactions that can prepare 
cyclic guanidines from simple precursors. Chapter 2 of this dissertation detail the development of 
a new approach to the synthesis of substituted 5-membered saturated cyclic guanidines. Palladium-
catalyzed alkene carboamination reactions between acyclic N-allyl guanidines and aryl or alkenyl 
halides provide these products in good yield. This method allows access to a number of different 
cyclic guanidine derivatives in only two steps from readily available allylic amines. Chapter 3 
expands upon this methodology by utilizing N-propargyl guanidines and aryl triflates in a 
carboamination reaction to afford the corresponding 2-aminoimidazole products. The utility of this 
reaction was demonstrated in the synthesis of the 2-aminoimidazole natural product preclathridine 
A.  
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Chapter 1 
Previous Strategies for the Synthesis of Guanidines 
1.1 Introduction: Biological Activity and Structural Characteristics of Mono-Cyclic 
Guanidines 
Cyclic guanidine natural products have garnered widespread attention due to their useful 
biological activity. Many of these alkaloids, which are most commonly extracted from marine 
sponges, contain 2-aminoimidazole rings (Figure 1.1). These molecules exhibit biological 
activities such as cytotoxicity,1,2 antimicrobial activity,3–5 and antibiotic activity.6 Furthermore, 
these molecules have been shown to be human β –secretase (BACE1) inhibitors,7,8 tubulin-binding 
agents,9,10 nitric oxidesynthase inhibitors,6 and epidermal growth factor receptor inhibitors.2,11,12 
As a result, molecules containing this structural motif have recently emerged as important 
pharmacophores in biomedical research.  
Representative examples of the different classes of 2-aminoimidazole containing natural 
products are shown in Figure 1.1. An identifying feature of these structures is the amino group on 
C-2. This amino group can be a secondary amine, as in the cases of the naamidine and clathridine 
family. The N-1 atom is most commonly substituted with a methyl group, while the N-3 position 
lacks substitution in most cases. This class of natural products gains most of its structural diversity 
through different substitution at the C-4 and C-5 position. In the naamidine and naamine family a 
substituent is linked to C-4 and C-5, while the preclathridine and clathridine family only features 
a substituent at C-5. Finally, the aromatic rings present in these molecules are typically oxygen 
rich. 
 
Figure 1.1 2-Aminoimidazole natural products 
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Five-membered saturated cyclic guanidine subunits are displayed in a number of natural 
products such as the araiosamines (e.g., araiosamine A, 1-1)13 and the plumbagine alkaloids.12,14,15 
These structures are also featured in a number of synthetic molecules with highly interesting 
biological activities. For example, simple monocyclic guanidine derivatives of general structure 
1-2 have demonstrated potent antimicrobial activity against drug-resistant Gram-positive bacteria 
including MRSA (methicillin-resistant Staphylococcus aureus).16–18 
 
Figure 1.2 Saturated 5-membered heterocyclic guanidine natural products 
 
 
 
  
 
Moreover, cyclic guanidines are synthetically useful organocatalysts.19 These organocatalysts 
can work by acting as Brønsted bases according to the catalytic cycle depicted in Scheme 1.1.20 
This general catalytic cycle begins with the deprotonation of substrate AH by the guanidine base 
1-3 to form the hydrogen bonding ion pair 1-4. B is then activated via another hydrogen bond, and 
the adduct A-B- adduct is formed. After protonation, the desired product A-BH is released, and the 
guanidine organocatalyst is regenerated.  
 
Scheme 1.1 Mechanism of guanidine organocatalysis.19  
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Monocyclic guanidines have also been employed as chiral organocatalysts. In 2000, Ishikawa 
and co-workers synthesized the cyclic guanidine (+)-Chiba-G (cat6), which is able to catalyze the 
reaction between imines and Michael acceptors, inducing high levels of enantioselectivity.20 The 
hydroxyl group in cat6 is an important secondary hydrogen bond donor, without this functional 
group, no reaction is observed.   
 
Scheme 1.2 The cyclic guanidine (+)-Chiba-G used as a chiral organocatalyst.20 
 
 
 
 
 
 
1.2 Previous Strategies and Limitations for the Cyclization of Guanidines 
Many research groups have developed methodology for the efficient cyclization of 
guanidines.21–29 Kim and co-workers developed an approach for the synthesis of disubstituted 
guanidines through the use of a Mitsunobu reaction followed by the addition of a primary amine 
to the recently formed guanylating agent. While developing this methodology, an interesting way 
of constructing cyclic guanidines was discovered.25 Interestingly, if an alcohol with a tethered 
amine (1-11) is coupled to the substrate, the compound can undergo cyclization in situ after 
undergoing the Mitsunobu reaction. Similarly, if a tethered ester is present in the alcohol (1-14), 
the Mitsunobu product can be sequentially treated with a primary amine to afford the cyclic 
guanidine product. While this reaction proceeds in good yield for primary alcohols, secondary 
alcohols are not well tolerated, making functionalization at C5 on the cyclic guanidine difficult to 
accomplish.  
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Scheme 1.3 Cyclization of guanidines via the addition of alcohols to guanylating agents under 
Mitsunobu conditions.25  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another classical method of guanidine cyclization, discovered by Shipman and co-workers, 
involves the formation of an electrophilic carbodiimide in situ, which then undergoes an 
intramolecular attack by an amine. This can be accomplished by converting an azide to an 
iminophosphorane in a Staudinger-type reaction, which then undergoes an aza-Wittig olefination 
to provide the aforementioned carbodiimide. Subsequently, this carbodiimide intermediate quickly 
undergoes an intramolecular cyclization to afford products such as 1-18.27 The utility of this 
methodology was demonstrated in the total synthesis of NA22598A1.  
 
Scheme 1.4 Guanidine cyclization from an azide starting material.27  
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A versatile hydroamination reaction recently published by the Looper group allows for the 
selective synthesis of both 5 and 6-membered cyclic guanidines by controlling the mode of 
cyclization (5-exo vs 6-endo) via a choice of catalyst and reaction conditions.22 Formation of the 
5-membered ring was highly selective in most cases, using a rhodium catalyst, while the 6-
membered ring was accomplished with silver catalysis. However, this extremely powerful 
constructions lack the ability to form a carbon-carbon bond in the ring closing event.  
 
Scheme 1.5 A highly versatile Rh-catalyzed hydroamination reaction.22  
 
 
 
In 2006, Du Bois reported a C-H functionalization reaction that was able to cyclize N-alkyl 
guanidines and ureas.26 The electron withdrawing group Tces (-SO3CH2Cl3) was proposed to 
deactivate the highly polar, Lewis basic nature of the guanidine nitrogen atoms, eliminating the 
need to protect both nitrogen atoms. Additional benefits of this protecting group include the ability 
to use simple, normal phase chromatography, and Tces deprotects readily when exposed to zinc. 
This impressive transformation was also proven to proceed stereospecifically, showing no erosion 
of chiral centers on substrates. The scope of the reaction tolerated a wide range of alkyl chains, 
however, unactivated, secondary methylene carbons failed to readily undergo the C-H activation 
reaction.  
 
Scheme 1.6 Formation of cyclic guanidines via C-H activation.26  
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While an impressive array of guanidine cyclizations exist, there are still limitations to 
methodologies in this field. A reaction that could induce late stage derivatization from an easily 
accessible substrate is highly desirable. Additionally, chiral cyclizations rely on installing 
stereocenters prior to cyclization, adding to the complexity of substrates, making them more 
difficult to prepare. If a stereoselective cyclization reaction could be developed, simple, acyclic 
substrates could be employed in a cyclization reaction. 
 
1.2 Pd-catalyzed Carboamination Reactions 
The Wolfe group has developed a series of carboamination reactions to form a number of 
nitrogen-containing heterocycles over the past decade (Scheme 1.7).30–32 These reactions form a 
heterocycle through the formation of a carbon-nitrogen bond, which is fashioned through a 
proposed syn-aminopalladation pathway (Scheme 1.8). A carbon-carbon bond is also formed from 
the cross-coupling of an aryl/alkenyl halide and an olefin tethered to the cyclizing amine. These 
products can be made in high yield and can proceed with excellent stereocontrol. A key advantage 
of this method is its usefulness for the rapid generation of analogues. Consequently, a variety of 
readily available aryl or alkenyl halides can be coupled with a single substrate to afford products 
with varying steric and electronic properties.    
The scope of this reaction has grown to include the cyclization of many nitrogen containing 
heterocycles.30 This carboamination reaction first began in 2004 with seminal work on the 
cyclization of γ-aminoalkene derivatives by Dr. Wolfe and Dr. Ney.33 This elegant chemistry can 
be used to access cis-2,5- and trans-2,3-disubstituted pyrrolidines in good yield and high 
diastereoselectivity. Additionally, stereocenters can be transferred from substrates without erosion 
of optical purity. Since this work, other 5-membered heterocycles, such as pyrazolidines,34 
isoxazolidines,35 and N-allyl ureas36,37 have been efficiently prepared.    
These transformations have been shown to proceed through the catalytic cycle shown in 
Scheme 1.8.30–32 The cycle begins with oxidative addition of a Pd(0) complex into the bond of an 
aryl halide, which then coordinates to the nitrogen to form complex 1-25. The 
palladium(aryl)amido complex  1-25 then undergoes the key syn-aminopalladation step to yield 1-
26, which generates the final cyclized product after the carbon-carbon bond forming reductive 
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elimination step. The stereochemistry of product 1-27 is achieved from performing syn-
aminopalladation on an (E)-olefin.   
 
Scheme 1.7 Scope of carboamination reactions with nitrogen-containing heterocycles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The substrate-controlled stereochemical oucome of these transformations found in Scheme 1.7 
is determined in the syn-aminopalladation step.31,32 Substrates substituted at C-1 form cis-2,5-
disubstituted pyrrolidines (1-31) due to the favored transition state 1-29. In this transition state, the 
substituent is placed in an axial position in order to avoid unfavorable steric interactions with the 
protecting group attached to the cyclizing nitrogen. When a disubstituted pyrrolidine is substituted 
in the allylic position, trans-2,3-disubstituted pyrrolidines are formed. The transition state leading 
to the trans product (1-34) is favored due to the substituent being placed in an equatorial position, 
avoiding unfavorable 1,3-diaxial interactions.   
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Scheme 1.8 Catalytic cycle and stereochemical rationale.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recently in the Wolfe group, a newly developed set of conditions have been discovered that 
exhibits a fundamentally different mechanism for migratory insertion.38 This set of conditions 
includes a key solvent change from the typical toluene solvent to the more polar trifluorotoluene 
solvent, and couples aryl triflates instead of aryl halides (Scheme 1.9). Preliminary results show 
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that 5-membered cyclic ureas and sulfamides can be readily prepared under these conditions. 
Deuterium labeling studies indicate that the migratory insertion step proceeds as anti addition as 
opposed to the aforementioned syn conditions. This reaction is of particular interest because it 
allows access to molecules with complimentary stereochemistry, and widens the stereochemical 
scope of molecules able to be fashioned through the use of carboamination chemistry.  
 
Scheme 1.9 Representative example of anti-aminopalladation.38  
 
 
 
 
 
Scheme 1.10 outlines a reasonable catalytic cycle for this reaction. Again, the mechanism 
begins with the oxidative addition of a Pd(0) complex into an aryl triflate. However, the palladium 
in complex 1-38 has a more cationic nature due to the triflate anion’s non-coordinating nature. 
This electrophilic palladium species coordinates to the olefin present in the substrate, which 
activates the olefin for an outer sphere attack from an amine nucleophile. This type of migratory 
insertion gives anti addition across the double bond. Reductive elimination then provides the 
desired product 1-41 and regenerates the Pd(0) catalyst.  
Recent work was published from our group detailing the employment of carboamination 
chemistry in elegant syntheses of complex cyclic guanidines, including the total synthesis of (+)-
merobatzelladine B (Figure 1.3).39,40 While this methodology has proven to be of great utility, the 
key carboamination reactions in these syntheses used urea substrates. The inability to use 
guanidine substrates costs additional steps in the syntheses. 
 
Figure 1.3 The tricyclic guanidine merobatzelladine B 
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In summary, carboamination reactions provide an efficient way to synthesize functionalized 
nitrogen-containing heterocycles, however, this strategy has never been successful for the 
construction of nitrogen-rich cyclic guanidine scaffolds. Due to the potentially useful bioactivity 
of these moieties, a distinct advantage of using this chemistry is the ability to rapidly generate 
analogues from a single substrate to create a library of drug candidates for screening. The ability 
to easily tune both steric and electronic parameters of pharmacaphores is an invaluable asset to 
medicinal chemistry. Thereupon, we set out to create a carboamination reaction that would be able 
to cyclize an easily accessible acyclic guanidine substrate to generate functionally and 
stereochemically complex cyclic guanidine products. Furthermore, we anticipated the successful 
development of this methodology would greatly aid in the synthesis of more complex guanidine 
natural products, including streamlining the synthesis of merobatzelladine B. 
 
Scheme 1.10 Catalytic cycle for anti-aminopalladation.38 
 
 
 
 
 
 
 
 
 
 
 
 
Overall, our general strategy was to construct a diverse group of cyclic guanidine products via 
carbomamination reactions between acyclic guanidine substrates and aryl or alkenyl halides and 
triflates. Chapter 2 details our development of Pd-catalyzed carboamination reactions that convert 
N-allyl guanidines and aryl or alkenyl halides to afford saturated 5-membered cyclic guanidines. 
15 
 
These reactions are proposed to proceed via syn-aminopalladation. Furthermore, chapter 3 outlines 
the optimization and scope of carboamination reactions between N-propargyl guanidines and aryl 
triflates, which create the corresponding 2-aminoimidazole products. In contrast to the 
methodology developed in chapter 2 these reactions are believed to proceed via anti-
aminopalladation. The utility of this reaction was illustrated in the total synthesis of preclathridine 
A. A key feature of the synthesis is potential ability to quickly generate a library of analogues. In 
summary, the research described in this dissertation details our development of Pd-catalyzed 
carboamination reactions for the efficient synthesis of cyclic guanidines. 
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Chapter 2 
Synthesis of Saturated Cyclic Guanidines via Pd-Catalyzed Alkene 
Carboamination Reactions 
2.1 Introduction 
As detailed in chapter one, saturated cyclic guanidines are molecules of significant 
importance.15 A well-studied example is the saxitoxin family (2-1). These molecules are known to 
inhibit voltage-gated Na+ ion channels, which generate the bioelectricity that is critical to many 
biological processes.26 Moreover, simpler, monocyclic guanidine natural products have also 
shown interesting properties. Plantago asiatica, a plant in which the seeds are used as a crude drug 
for diuretic, antitussive, expectorant, and antiphlogistic purposes, was recently shown to contain 
plantagoguanidinic acid (2-2), a saturated cyclic guanidine, as a component.41  
 
Figure 2.1 Saturated cyclic guanidine natural products.41,42 
 
 
 
 
 
2.2 Synthetic Strategy 
Our strategy for constructing cyclic guanidines began with designing a substrate that could be 
prepared in a high yielding, scalable fashion. As such, a protected N-methyl allyl guanidine would 
be an ideal starting point, as these molecules can be prepared from common allylic amines.43,44 
This substrate would then be able to be coupled with an aryl bromide in a carboamination reaction 
to afford the desired cyclic product. We believed that a key challenge of this reaction was 
decreasing the basicity of the nitrogen nucleophile, as it could participate in an undesirable N-
arylation side reaction45 and/or bind to the catalyst46 through covalent interactions. 
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2.3 Optimization of Reaction Conditions 
Previous work from the Wolfe group showed that bis-Boc protected N-methylallyl guanidine 
2-3 underwent the desired carboamination reaction with 2-bromonaphthalene. Further exploration 
revealed that a catalyst composed of Pd2(dba)3 and Xantphos provided the best results as substrate 
2-3 was coupled with 2-bromonaphthalene and 4-bromotoluene to afford products 2-4 and 2-5 in 
moderate yield. However, these reactions were highly variable with poor reproducibility. Further 
experiments showed that the bis-Boc protected substrate and carboamination product were both 
susceptible to base mediated decomposition under the reaction conditions. Thus, employing less 
labile protecting groups was a logical next step in the reaction optimization.  
After failed attempts with readily prepared alkyl protected guanidines, the electron-rich PMP 
(p-methoxyphenyl) protecting group was utilized. We were pleased to see that the substrate 2-4, 
employed as the HCl salt, underwent the desired reaction to 2-6 and 2-7 in good yield, with 
excellent reproducibility. We also explored the triflate salt of the substrate, but this substrate was 
difficult to purify and less convenient to handle. Superior results were found when the bidentate 
ligand Nixantphos was used in combination with Pd2(dba)3, while other similar ligands gave 
inferior yields. Interestingly, using 8 mol % of a bidentate ligand in combination with 2 mol % of 
Pd2(dba)3 gave much better results when compared to the typically used stoichiometry of 4 mol % 
for a bidentate ligand. 
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Table 2.1 Selected results from ligand and protecting group screen.a 
 
 
 
 
 
 
 
 
2.4 Scope of Carboamination Reaction 
In order to investigate the scope of the cyclization reaction, we varied the electronic and 
structural properties of the aryl halide participating in the carboamination reaction (Table 2.2). We 
were pleased to see that electron-rich, electron-neutral, and electron-poor aryl halides were well 
tolerated under these reaction conditions (entries 1-6). Furthermore, an ortho substituted aryl 
halide (entry 8) also showed satisfactory results. Although these reactions were generally high-
yielding, substrate 2-4 was observed to undergo an undesired deallylation side reaction. 
Furthermore, the carboamination products were prone to silica gel mediated oxidation during 
column chromatography, resulting in the formation of the corresponding 2-aminoimidazole. 
Entry Substrate R1 Ligand Product Yieldb (%) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
 
2-3 
2-3 
2-3 
2-3 
2-3 
2-3 
2-4 
2-4 
2-4 
2-4 
2-naphthyl 
4-tolyl 
2-naphthyl 
4-tolyl 
2-naphthyl 
4-tolyl 
2-naphthyl 
4-tolyl 
2-naphthyl 
4-tolyl 
Xantphos 
Xantphos 
Nixantphos 
Nixantphos 
Dpe-phos 
Dpe-phos 
Xantphos 
Xantphos 
Nixantphos 
Nixantphos 
2-4 
2-5 
2-4 
2-5 
 
 
2-6 
2-7 
2-6 
2-7 
20 (66) 
 (26) 
33 (41) 
26 (53) 
0 
0 
(74) 
(65) 
57 (81) 
73 (77) 
a Conditions: 1.0 equiv of guanidine substrate, 1.5 equiv of R1–Br, 2.4 equiv of NaOtBu, 2 mol % Pd2(dba)3, 8 
mol % ligand, toluene (0.1 M), 107 °C. Reactions of 2-4 were quenched with an excess of acqueous HCl (1 M) to 
ensure complete protonation of the guanidine. b Isolated yields. Numbers in parentheses are NMR yields based on 
phenanthrene as an internal standard. 
 
19 
 
Therefore, a new substrate (2-5) that would abate these side reactions was tested. Expectedly, 
this molecule, bearing an internally methyl substituted olefin, showed improved yields with 
previously used aryl halides (entries 9-10). Additionally, a diverse group of electrophiles were able 
to participate in the reaction. To our delight, an alkenyl halide was coupled to the guanidine 
substrate in good yield (Z-1-bromobutene, entry 11), as well as a 5-membered heterocyclic halide 
(2-bromothiophene, entry 12). 
To probe the stereoselectivity of the reaction, substrates 2-6a, 2-6b, and 2-7 were prepared. 
The reaction between E-alkene 2-6a and 4-bromotoluene provided product 2-22a in excellent dr 
(>20:1), albeit in low yield. Unfortunately, the analogous methyl substituted E-alkene (2-6b) gave 
a complex mixture of products. Substrate 2-7, substituted at the allylic position, gave good yield 
but poor stereoselectivity (dr = 2:1). Rationale for the stereochemical outcome of these reactions 
can be found in Scheme 1.8, which describes the proposed catalytic cycle for Pd-catalyzed 
carboamination reactions that proceed via syn-aminopalladation. 
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Table 2.2 Pd-Catalyzed Carboamination of N-allylguanidinesa 
 
 
 
 
Entry Substrate Product Yield (%)b 
 
1 
 
2 
 
 
 
3 
 
 
 
 
 
4 
 
 
 
 
 
5 
 
 
 
 
 
6 
 
 
 
 
 
7 
 
 
 
 
 
 
8 
 
   
76 
(X = I) 
73 
(X = Br) 
 
 
62 
(X = I) 
 
 
 
 
72 
(X = Br) 
 
 
 
 
65 
(X = I) 
 
 
 
 
78 
(X = Br) 
 
 
 
 
83 
(X = Br) 
 
 
 
 
 
75c 
(X = Br) 
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Entry Substrate Product Yield (%)b 
 
 
9 
 
 
 
 
 
10 
 
 
 
 
 
11 
 
 
 
 
 
12 
 
 
 
 
 
 
 
13 
 
 
14 
 
 
 
 
 
15 
 
 
 
 
 
   
 
99 
(X = Br) 
 
 
 
 
99 
(X = Br) 
 
 
 
 
98 
(X = Br) 
 
 
 
 
86d 
(X = Br) 
 
 
 
 
 
 
R = Ph 
21 
>20:1 dr 
(X = Br) 
 
 
 
 
 
62 
2:1 dr 
(X = Br) 
a Conditions: 1.0 equiv of guanidine substrate, 1.5 equiv of R1–X, 2.4 equiv of NaOtBu, 2 mol % Pd2(dba)3, 8 
mol % ligand, toluene (0.1 M), 107 °C. Reactions were quenched with an excess of acqueous HCl (1 M) to ensure 
complete protonation of the guanidine. b Isolated yields (average of two experiments). Diastereomeric ratios (dr) 
were deteremined by 1H NMR analysis of the isolated products; diastereomeric ratios did not change significantly 
during purification. c This product contains ca. 8% of a side product tentatively assigned as the analogous 2-
aminoimidazole. d This reaction was conducted using 4.0 equiv of the alkenyl bromide and 4.5 equiv of NaOtBu. e 
Substrate 2-6b was employed as a 7:1 mixture of E:Z alkene isomers.  
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2.5 Deprotection and Asymmetric Induction 
In hopes of showcasing the synthetic utility of this reaction, removal of the PMP protecting 
groups was attempted. Initial attempts showed that one group can be deprotected, though in modest 
yield. As an attempt to avoid this issue, the free guanidine substrate 2-22 was submitted to the 
reaction conditions. Unfortunately, this reaction gave a complex mixture of products and did not 
lead to the isolation of any cyclic guanidine product.  
 
Scheme 2.1 Attempts at synthesizing deprotected product 
 
 
 
 
 
 
Past efforts at asymmetric induction in our group have shown success with similar molecules, 
cyclizing N-allylureas and N-(pent-4-enyl)carbamates in good yield and with high 
enantioselectivity.47,48 We hoped that guanidines would also be able to undergo an effective 
asymmetric carboamination reaction. We began these studies by examining the effects of 
monodentate phosphoramidite ligands (S)- and (R)-Siphos-PE, ligands that had shown success 
with earlier projects. A screen of other chiral ligands showed that the chelating bidentate ligands 
(S)-Phanephos and (S)-BINAP afforded the desired product in good yield, but with poor 
enantioselectivity (Table 2.3). While these results show that asymmetric induction is indeed 
feasible, further optimization studies will be needed to identify the correct catalytic system.  
 
2.6 Conclusions  
In summary, we have utilized Pd-catalyzed alkene carboamination reactions as a convenient 
route to the synthesis of substituted 5-membered cyclic guanidines. These reactions allow for the 
facile derivitization of these products in only two steps from the easily preparable allylic amines. 
This work is the first example of Pd-catalyzed alkene carboamination reactions of guanidine 
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nucleophiles. Future work will be dedicated to expanding the scope and improving the 
enantioselectivity of the asymmetric carboamination reaction.  
 
 
Table 2.3 Preliminary Studies on Asymmetric Catalysisa 
 
 
 
 
 
 
 
 
 
 
a Conditions: 1.0 equiv of 2-5, 1.5 equiv of 4-bromotoluene, 2.4 equiv of NaOtBu, 2 mol % Pd2(dba)3, 8 mol % 
ligand (for chelating ligands) or 16 mol % ligand (for monodentate ligands), toluene (0.1 M), 107 ºC. Reactions were 
quenched with an excess of aqueous HCl (1 M) to ensure complete protonation of the guanidine. b Isolated yields. 
cEnantiomeric ratios were determined by the cleavage of one PMP group from the product followed by conversion to 
the Mosher amide and analysis by 1H NMR.  
 
The work described in this chapter was published in Organic Letters.49 
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2.7 Experimental 
 
General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware 
unless otherwise noted. Tris(dibenzylidene)acetone dipalladium and Nixantphos were purchased 
from Strem Chemical Co. and used without purification. All other reagents were obtained from 
commercial sources and were used as obtained unless otherwise noted. (Z)-1-bromobutene50 was 
prepared according to a slight modification of a literature procedure; the preparation was 
conducted at rt instead of using microwave heating. N-methylbut-2-en-1-ylamine was prepared as 
a 7:1 mixture of E:Z alkene isomers according to a published procedure.51 Sodium tert-butoxide 
was kept in a glove box and removed only prior to use. Toluene, THF, diethyl ether and 
dichloromethane were purified using a GlassContour solvent purification system. Yields refer to 
isolated yields of compounds estimated to be ≥95% pure as determined by 1H NMR analysis unless 
otherwise noted. The yields reported in the supporting information describe the result of a single 
experiment, whereas isolated yields reported in Tables 1–2 are averages of yields for two or more 
experiments. Thus, the yields reported in the supporting information may differ from those shown 
in Tables 1–2.  
Preparation and Characterization of Guanidine Substrates 
 
 
N1-Allyl-N2,N3-Bis(tert-butoxycarbonyl)-N1-methylguanidine (2-3). The title compound was 
prepared using the general guanylation procedure reported by Lipton.43 A flame-dried flask 
equipped with a stirbar was cooled under a stream of N2, and charged with N,N’-bis-Boc-thiourea 
(1.79 g, 6.45 mmol), dichloromethane (65 mL), N-methylallylamine (518 uL, 5.4 mmol), 
triethylamine (1.66 mL, 11.9 mmol), and N-methyl-2-chloropyridinium iodide (1.64 g, 6.42 
mmol). The resulting solution was stirred overnight (16 h) at rt. Water was added to the reaction 
flask, the mixture was stirred at rt for 5 min, then was transferred to a separatory funnel. The layers 
were separated and the organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography on silica gel to 
afford 660 mg (39%) of the title compound as a white solid: mp = 71–74 ºC. This compound was 
found to exist as a mixture of rotamers as judged by 1H and 13C NMR analysis; data are for the 
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mixture.  1H NMR (700 MHz, CDCl3)  10.05 (s, 1 H), 5.86–5.81 (m, 1 H), 5.26–5.21 (m, 2 H), 
4.08 (s, br, 2 H), 2.96 (s, 3 H), 1.49 (s, 18 H); 13C NMR (175 MHz, CDCl3)  182.0, 162.6, 155.9, 
151.2, 132.7, 118.5, 84.2, 81.9, 79.4, 53.4, 36.4, 28.1, 27.9; IR (film) 3286, 3175, 1748, 1612 cm–
1. MS (ESI) 314.2073 (314.2074 calcd for C15H27N3O4, M + H
+). 
 
 
N,N'-Methanediylidene-bis-(4-methoxyaniline) (S1). The title compound was prepared using a 
procedure published by Coppola.52 A flame-dried flask was cooled under a stream of N2, charged 
with 1,3-bis(4-methoxyphenyl)thiourea (5.67 g, 19.6 mmol), 4-dimethylaminopyridine (96.0 mg, 
0.786 mmol), methanesulfonyl chloride (1.7 mL, 21.6 mmol), triethylamine (8.2 mL, 58.9 mmol), 
and dichloromethane (196 mL, 0.1 M). The resulting solution was stirred at 0 ºC for 5 min. The 
solution was then filtered through a plug of silica gel, and the silica gel was washed with 300 mL 
of a 1:1 mixture of ethyl acetate and hexanes. The filtrate was concentrated in vacuo. The crude 
material was purified by flash chromatography on silica gel to afford 3.98 g (80%) of the title 
compound as a white solid. Spectroscopic properties were identical to those previously reported:50 
mp = 48–50 ºC (lit.53 mp = 48–50 °C). 1H NMR (400 MHz, CDCl3)  7.11 (d, J = 8.8 Hz, 4 H), 
6.85 (d, J = 8.8 Hz, 4 H), 3.80 (s, 6 H). 
 
General Procedure for Synthesis of Bis(4-methoxyphenyl)guanidine Substrates. The bis(4-
methoxyphenyl)guanidine derivatives were synthesized using a modification of a procedure 
published by Xi.44 A flame dried round-bottom flask equipped with a stirbar was cooled under a 
stream of N2, and charged with N,N'-methanediylidene-bis-(4-methoxyaniline) (1.0 equiv), the 
appropriate amine (1.2 equiv), zinc chloride (1 equiv), dichloromethane (0.025 M), and diethyl 
ether (0.25 M). The resulting mixture was stirred overnight at rt, then was filtered through a plug 
of celite, and the celite plug was washed with dichloromethane (150 mL). The filtrate was washed 
with 1M aqueous HCl (5 mL/mmol) and saturated aqueous sodium chloride (5 mL/mmol). The 
organic layer was then concentrated in vacuo and the resulting crude product was purified by flash 
chromatography on silica gel.  
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1-Allyl-2,3-bis(4-methoxyphenyl)-1-methylguanidine hydrochloride (2-4). The title compound 
was prepared from N,N'-methanediylidene-bis-(4-methoxyaniline) (1.68 g, 6.61 mmol) and N-
methylallylamine (0.8 mL, 7.93 mmol) according to the general procedure. This procedure 
afforded 1.43 g (60%) of the title compound as a white foam solid: mp = 77–79 ºC. 1H NMR (500 
MHz, CDCl3)  10.03 (s, 2 H), 7.00 (d, J = 9.0 Hz, 4 H), 6.55 (d, J = 8.0 Hz, 4 H), 5.88–5.78 (m, 
1 H), 5.31–5.21 (m, 2 H), 4.13 (s, 2 H), 3.64 (s, 6 H), 3.08 (s, 3 H); 13C NMR (125 MHz, CDCl3) 
 157.0, 154.2, 131.4, 129.7, 123.7, 120.3, 114.1, 55.4, 55.3, 38.1; IR (film) 3203, 1625 cm–1. MS 
(ESI) 326.1863 (326.1866 calcd for C19H24N3O2, M
+).  
 
 
 
1-Ethyl-2,3-bis(4-methoxyphenyl)-1-(2-methylallyl)guanidine hydrochloride (2-5). The title 
compound was prepared from N,N'-methanediylidene-bis-(4-methoxyaniline) (2.06 g, 8.09 mmol) 
and N-ethyl-2-methylallylamine (1.28 mL, 9.7 mmoL) according to the general procedure except 
the N-ethyl-2-methylallylamine was filtered through a plug of silica gel prior to addition, and the 
silica plug was eluted with 5 mL of dichloromethane, which was added to the reaction mixture. 
This procedure afforded 2.43 g (73%) of the title compound as a white foam solid: mp = 68 ºC. 1H 
NMR (500 MHz, CDCl3)  6.92 (d, J = 8.0 Hz, 4 H), 6.56 (d, J = 8.0 Hz, 4 H), 4.99 (s, 1 H), 4.92 
(s, 1 H), 4.09 (s, 2 H), 3.66 (s, 6 H), 3.63–3.58 (m, 2 H), 1.74 (s, 3 H), 1.17 (t, J = 7.0 Hz, 3 H); 
13C NMR (175 MHz, CDCl3)  156.8, 153.9, 139.7, 129.9, 123.6, 114.5, 114.0, 55.9, 55.3, 45.4, 
20.3, 13.2; IR (film) 3040, 1619 cm–1. MS (ESI) 354.2180 (354.2176 calcd for C21H28N3O2, M
+). 
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1-Cinnamyl-2,3-bis(4-methoxyphenyl)-1-methylguanidine hydrochloride (2-6a). The title 
compound was prepared from commercially available cinnamyl bromide via a two-step procedure. 
A round-bottom flask equipped with a stirbar was charged with cinnamyl bromide (5.9 g, 30 mmol) 
and ethanol (30 mL) and cooled to 0 oC.  Methylamine (37.5 mL, 300 mmol, 33% solution in 
ethanol) was slowly added to the reaction flask over the course of 10 min. The reaction mixture 
was allowed to warm rt and was stirred overnight. The reaction mixture was concentrated, 
dissolved in dichloromethane (100 mL), and transferred to a separatory funnel. 1 M HCl (20 mL) 
was added to the separatory funnel and the layers were separated. The organic layer was washed 
again with 1 M HCl (20 mL). The combined aqueous layers were transferred to a round-bottom 
flask and dichloromethane (50mL) was added. The biphasic mixture was basified with NH4OH to 
pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer 
was extracted with dichloromethane (3 x 15 mL). The combined organic layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude N-methylcinnamylamine 
was then coupled with N,N'-methanediylidene-bis-(4-methoxyaniline) (4.3 g, 17.0 mmol) 
according to the general procedure described above. This procedure afforded 1.82 g (27%) of the 
title compound as an off-white solid: mp = 84–89 ºC. 1H NMR (500 MHz, CDCl3)  8.70 (s, br, 2 
H), 7.33–7.20 (m, 5 H), 7.18 (d, J = 9.0 Hz, 4 H), 6.75 (d, J = 8.5 Hz, 4 H), 6.49 (d, J = 16.5 Hz, 
1 H), 6.02–5.97 (m, 1 H), 4.15 (s, br, 2 H), 3.67 (s, 6 H), 2.99 (s, 3 H); 13C NMR (175 MHz, 
CDCl3)  157.6, 154.8, 135.8, 135.6, 129.3, 128.6, 128.1, 126.7, 124.4, 121.6, 114.7, 55.4, 54.9, 
37.7; IR (film) 3256, 3205, 1627 cm–1. MS (ESI) 402.2176 (402.2176 calcd for C25H28N3O2, M
+). 
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1-(But-2-en-1-yl)-2,3-bis(4-methoxyphenyl)-1-methylguanidine hydrochloride (2-6b). The 
title compound was prepared from N,N'-methanediylidene-bis-(4-methoxyaniline) (778 mg, 3.06 
mmol) and N-methylbut-2-en-1-amine (employed as a 7:1 mixture of E:Z alkene isomers and as a 
20% solution in EtOH) (260 mg, 3.06 mmol, 1.0 equiv,) according to the general procedure. After 
purification by flash column chromatography, 448 mg (39%) of the title compound was obtained 
as a pale brown solid (mp: 58–63 ºC) and as a 7:1 mixture of E:Z alkene isomers as determined by 
1H NMR analysis. The 1H data contains dichloromethane which was difficult to remove in vacuo. 
The data is for the mixture. 1H NMR (500 MHz, CDCl3) δ 8.57 (s, 2 H), 7.17–7.13 (m, 4 H), 6.81–
6.78 (m, 4 H), 5.73–5.66 (m, 1 H), 5.37–5.32 (m, 1 H), 3.93 (d, J = 5 Hz, 2 H), 3.73 (s, 6 H), 2.92 
(s, 3 H), 1.69 (d, J = 5.5 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 157.7, 157.4, 154.5, 133.0, 
131.2, 129.3, 125.0, 124.3, 123.1, 114.7, 114.7, 55.5, 55.5, 54.7, 37.6, 17.8; IR (film) 3247, 2954, 
1627 cm–1. MS (ESI) 340.2019 (340.2020 calcd for C20H25N3O2, M+). 
 
 
 
(±)-N,N'-Bis(4-methoxyphenyl)-2-vinylpyrrolidine-1-carboximidamide hydrochloride (2-7). 
The title compound was prepared from commercially available N-Boc-2-vinylpyrrolidine via a 
two-step procedure. A round-bottom flask equipped with a stirbar was charged with N-Boc-2-
vinylpyrrolidine (2.5 mL, 12.5 mmol) and dichloromethane (25 mL). Trifluoroacetic acid (12.5 
mL, 1.0 M) was added to the flask and the mixture was stirred at rt for 1 h until the starting material 
had been completely consumed as judged by TLC analysis. The solution was diluted with water, 
basified with NH4OH to pH > 12, and transferred to a separatory funnel. The layers were separated 
and the aqueous layer was extracted with dichloromethane (3 x 10 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
amine was then coupled with N,N'-methanediylidene-bis-(4-methoxyaniline) (3.2 g, 12.5 mmol) 
according to the general procedure described above. This procedure afforded 464 mg (10%) of the 
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title compound as a pale yellow solid: mp = 58–62 ºC. 1H NMR (700 MHz, CD3OD)  7.00 (d, J 
= 9.1 Hz, 4 H), 6.82 (d, J = 9.1 Hz, 4 H), 5.90–5.85 (m, 1 H), 5.27–5.22 (m, 2 H), 4.58–4.55 (m, 
1 H), 3.73 (s, 6 H), 3.67–3.63 (m, 1 H), 3.58–3.54 (m, 1 H), 2.30–2.26 (m, 1 H), 2.08–2.04 (m, 1 
H), 2.01–1.95 (m, 1 H), 1.87–1.82 (m, 1 H); 13C NMR (175 MHz, CD3OD)  159.4, 153.8, 137.6, 
130.7, 125.9, 118.4, 115.6, 63.5, 56.0, 51.4, 33.7, 25.0; IR (film) 3204, 1629 cm–1. MS (ESI) 
352.2020 (352.2020 calcd for C21H26N3O2, M
+). 
 
 
1-Allyl-1-methylguanidinium trifluoroacetate (2-22). A round-bottom flask equipped with a 
stirbar was charged with 2-3 (196 mg, 0.63 mmol) and dichloromethane (2.4 mL). Trifluoroacetic 
acid (0.9 mL) was added to the flask and the reaction mixture was stirred overnight at rt, and the 
solution was then concentrated in vacuo. Toluene (4 mL) was added and the resulting solution was 
concentrated in vacuo. The addition of toluene and subsequent concentration was repeated (3x) to 
remove all excess trifluoroacetic acid, at which time the compound was obtained as a crystalline 
white solid: mp = 159–164 °C. This procedure afforded 85 mg (60%) of the title compound. This 
material also contained ca. 10% of an unidentified side product. 1H NMR (500 MHz, CD3OD) δ 
5.83–5.75 (m, 1 H), 5.26–5.17 (m, 2 H), 3.95 (d, 2 H), 2.99 (s, 3 H); 13C NMR (125 MHz, CD3OD) 
δ 159.4, 132.8, 118.9, 45.4, 37.3; IR (film) 3312, 3150, 1663 cm–1. MS (ESI) 114.1028 (114.1026 
calcd for C5H11N3, M+). 
Preparation and Characterization of Cyclic Guanidine Products 
General Procedure for Pd-Catalyzed Synthesis of Cyclic Guanidines. A flame-dried Schlenk 
tube was cooled under vacuum and charged with the appropriate guanidine substrate (1.0 equiv), 
Pd2(dba)3 (0.02 equiv), Nixantphos (0.08 equiv), and NaOtBu (1.5 equiv). The flask was evacuated 
and purged with N2. Toluene (0.1 M) was added via syringe and the resulting mixture was stirred 
at rt for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was 
heated to 107 ºC and stirred overnight (~16 h). The mixture was cooled to room temperature and 
1 M HCl (10 mL/mmol substrate) and dichloromethane (25 mL/mmol substrate) were added. The 
layers were separated and the aqueous layer was exctracted with dichloromethane (10 mL/mmol). 
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The organic layers were combined and concentrated in vacuo. The crude material was purified by 
flash chromatography on silica gel. 
 
 
 
tert-Butyl-2-[(tert-butoxycarbonyl)imino]-3-methyl-5-(naphthalen-2-
ylmethyl)imidazolidine-1-carboxylate (2-4). The general procedure was employed for the 
coupling of 2-3 (94 mg, 0.3 mmol) and 2-bromonaphthalene (93 mg, 0.45 mmol) using a catalyst 
composed of Pd2(dba)3 (5.5 mg, 0.006 mmol) and Nixantphos (13 mg, 0.024 mmol). Saturated 
aqueous NH4Cl was used during the workup instead of 1 M HCl. This procedure afforded 43 mg 
(33%) of the title compound as an off-white solid: mp = 56–58 ºC. This compound was found to 
exist as a mixture of rotamers as judged by 1H and 13C NMR analysis; data are for the mixture.  1H 
NMR (700 MHz, CDCl3)  7.81–7.79 (m, 3 H), 7.70 (s, 1 H), 7.48–7.43 (m, 2 H), 7.36 (dd, J = 
1.4, 8.4 Hz, 1 H), 4.47–4.44 (m, 1 H), 3.44–3.40 (m, 1 H), 3.35 (dd, J = 4.9, 14.0 Hz, 1 H), 3.07 
(dd, J = 2.1, 9.8 Hz, 1 H), 2.93 (dd, J = 9.1, 14.0 Hz, 1 H), 2.83 (s, 3 H), 1.54 (s, 9 H), 1.45 (s, 9 
H); 13C NMR (175 MHz, CDCl3)  159.6, 151.5, 149.8, 133.9, 133.5, 132.4, 128.4, 128.2, 127.6, 
127.6, 127.5, 126.2, 125.8, 82.5, 78.7, 56.7, 49.9, 40.2, 32.1, 28.3, 28.1; IR (film) 1748, 1629 cm–
1. MS (ESI) 440.2538 (440.2544 calcd for C25H33N3O4, M + H
+). 
 
 
 
tert-Butyl 2-[(tert-butoxycarbonyl)imino]-3-methyl-5-(4-methylbenzyl)imidazolidine-1-
carboxylate (2-5). The general procedure was employed for the coupling of 2-3 (63 mg, 0.2 mmol) 
and 4-bromotoluene (51 mg, 0.3 mmol) using a catalyst composed of Pd2(dba)3  (3.7 mg, 0.004 
mmol) and Nixantphos (8.8 mg, 0.016 mmol). Saturated aqueous NH4Cl was used during the 
workup instead of 1 M HCl. This procedure afforded 21 mg (26%) of the title compound as a pale 
yellow oil. This compound was found to exist as a mixture of rotamers as judged by 1H and 13C 
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NMR analysis; data are for the mixture. 1H NMR (700 MHz, CDCl3)  7.12 (d, J = 7.7 Hz, 2 H), 
7.09 (d, J = 7.7 Hz, 2 H), 4.29–4.26 (m, 1 H), 3.25–3.21 (m, 2 H), 3.04 (dd, J = 2.8, 9.1 Hz, 1 H), 
2.76 (s, 3 H), 2.65 (dd, J = 9.8, 13.3 Hz, 1 H), 2.32 (s, 3 H), 1.57 (s, 9 H), 1.45 (s, 9 H); 13C NMR 
(175 MHz, CDCl3)  165.5, 154.1, 150.6, 136.5, 133.3, 129.4, 129.2, 82.3, 53.2, 47.7, 39.0, 30.5, 
28.2, 21.0; IR (film) 1750, 1627 cm–1. MS (ESI) 404.2545 (404.2544 calcd for C22H33N3O4, M + 
H+). 
 
 
N,3-Bis(4-methoxyphenyl)-1-methyl-4-(naphthalen-2-ylmethyl)imidazolidin-2-imine 
hydrochloride (2-6): The general procedure was employed for the coupling of 2-4 (54 mg, 0.15 
mmol) and 2-bromonaphthalene (47 mg, 0.23 mmol) using a catalyst composed of Pd2(dba)3  (2.7 
mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 42 mg (57%) 
of the title compound as a pale yellow-brown foam solid: mp = 67–68 ºC. 1H NMR (500 MHz, 
CDCl3)  7.80–7.77 (m, 3 H), 7.60 (s, 1 H), 7.50–7.46 (m, 2 H), 7.21 (d, J = 8.0 Hz, 1 H), 7.04–
7.02 (m, 2 H), 6.97–6.94 (m, 2 H), 6.63–6.60 (m, 2 H), 6.52–6.49 (m, 2 H), 4.50–4.44 (m, 1 H), 
3.83–3.79 (m, 1 H), 3.70–3.68 (m, 3 H), 3.39–3.36 (m, 3 H), 3.61–3.59 (m, 1 H), 3.39–3.62 (m, 3 
H), 3.23–3.19 (m, 1 H), 3.04 (dd, J = 10.0, 13.0 Hz, 1 H); 13C NMR (125 MHz, CDCl3)  159.2, 
157.7, 156.5, 133.4, 132.5, 132.4, 132.4, 132.3, 129.5, 128.8, 128.0, 127.7, 127.5, 126.9, 126.6, 
126.6, 126.1, 114.6, 113.8, 63.8, 55.5, 55.4, 54.0, 39.5, 35.7; IR (film) 3050, 1632 cm–1. MS (ESI) 
452.2328 (452.2333 calcd for C29H30N3O2, M
+). 
 
 
 
N,3-Bis(4-methoxyphenyl)-1-methyl-4-(4-methylbenzyl)imidazolidin-2-imine hydrochloride 
(2-7): The general procedure was employed for the coupling of 2-4 (54 mg, 0.15 mmol) and 4-
iodotoluene (49 mg, 0.23 mmol) using a catalyst composed of Pd2(dba)3  (2.7 mg, 0.003 mmol), 
and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 42 mg (62%) of the title compound 
as a pale yellow-brown foam solid: mp = 73–75 ºC. 1H NMR (500 MHz, CDCl3)  7.14 (d, J = 8.5 
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Hz, 2 H), 7.11–7.06 (m, 4 H), 7.02 (d, J = 8.0 Hz, 2 H), 6.67 (d, J = 9.0 Hz, 2 H), 6.56  (d, J = 9.0 
Hz, 2 H), 4.49–4.42 (m, 1 H), 3.90–3.86 (m, 1 H), 3.72 (s, 3 H), 3.66 (s, 3 H), 3.60 (dd, J = 7.5, 
10.0 Hz, 1 H), 3.23 (s, 3 H), 2.96 (dd, J = 4.5, 13.5 Hz, 1 H), 2.91 (dd, J = 10.0, 13.5 Hz, 1 H), 
2.30 (s, 3 H); 13C NMR (125 MHz, CDCl3)  159.4, 158.2, 156.1, 137.0, 131.8, 129.6, 129.2, 
129.0, 128.7, 127.7, 126.9, 114.8, 113.9, 63.6, 55.6, 55.5, 54.2, 38.4, 36.2, 21.0; IR (film) 3133, 
1631 cm–1. MS (ESI) 416.2340 (416.2333 calcd for C26H30N3O2, M
+). 
 
 
 
N,3-Bis(4-methoxyphenyl)-1-methyl-4-(4-methylbenzyl)imidazolidin-2-imine hydrochloride 
(2-8): The general procedure was employed for the coupling of 2-4 (54 mg, 0.15 mmol) and 4-
bromotoluene (39 mg, 0.225 mmol) using a catalyst composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), 
and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 50 mg (73%) of the title compound 
as a pale yellow-brown foam solid. Spectroscopic data were identical to those provided above. 
 
 
 
4-[4-(1H-Pyrrol-1-yl]benzyl)-N,3-bis(4-methoxyphenyl)-1-methylimidazolidin-2-imine 
hydrochloride (2-9): The general procedure was employed for the coupling of 2-4 (54 mg, 0.15 
mmol) and 1-(4-iodophenyl)pyrrole (61 mg, 0.23 mmol) using a catalyst composed of Pd2(dba)3 
(2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 48 mg 
(63%) of the title compound as a pale yellow-brown foam solid: mp = 70–71 ºC. 1H NMR (500 
MHz, CDCl3)  7.30 (d, J = 8.0 Hz, 2 H), 7.21–7.17 (m, 4 H), 7.14 (d, J = 8.5 Hz, 2 H), 7.04 (t, J 
= 2.5 Hz, 2 H), 6.69 (d, J = 9.0 Hz, 2 H), 6.58 (d, J = 9.0 Hz, 2 H), 6.33 (t, J = 3.0 Hz, 2 H), 4.58–
4.51 (m, 1 H), 3.95–3.91 (m, 1 H), 3.72 (s, 3 H), 3.70–3.68 (m, 1 H), 3.67 (s, 3 H), 3.22 (s, 3 H), 
3.06–3.04 (m, 2 H); 13C NMR (125 MHz, CDCl3)  159.4, 158.2, 156.2, 139.8, 132.4, 130.3, 129.3, 
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128.6, 127.7, 127.0, 120.7, 119.2, 114.8, 113.9, 110.6, 63.5, 55.6, 55.5, 54.3, 38.2, 36.0; IR (film) 
3058, 1635 cm–1. MS (ESI) 467.2450 (467.2442 calcd for C29H31N4O2, M
+). 
 
 
 
4-Benzyl-N,3-bis(4-methoxyphenyl)-1-methylimidazolidin-2-imine hydrochloride (2-10): 
The general procedure was employed for the coupling of 2-4 (54 mg, 0.15 mmol) and 
bromobenzene (24 µL, 0.23 mmol) using a catalyst composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), 
and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 48 mg (73%) of the title compound 
as a pale yellow-brown foam solid: mp = 58–59 ºC. 1H NMR (500 MHz, CDCl3)  7.31 (t, J = 7.0 
Hz, 2 H), 7.27–7.26 (m, 1 H), 7.13 (d, J = 8.0 Hz, 2 H), 6.98 (d, J = 9.0 Hz, 2 H), 6.92  (d, J = 9.0 
Hz, 2 H), 6.61 (d, J = 8.5 Hz, 2 H), 6.50 (d, J = 9.0 Hz, 2 H), 4.34–4.27 (m, 1 H), 3.83–3.78 (m, 1 
H), 3.69 (s, 3 H), 3.65 (s, 3 H), 3.51 (dd, J = 3.5, 13.5 Hz, 1 H), 3.40 (s, 3 H), 3.06 (dd, J = 3.5, 
13.5 Hz, 1 H), 2.85 (dd, J = 10.0, 14.0 Hz, 1 H); 13C NMR (125 MHz, CDCl3)  159.0, 157.5, 
156.5, 135.0, 129.9, 129.1, 129.0, 128.6, 128.3, 127.5, 126.5, 114.5, 113.8, 63.9, 55.5, 55.5, 53.8, 
39.5, 35.4; IR (film) 3003, 1640 cm–1. MS (ESI) 402.2177 (402.2176 calcd for C25H28N3O2, M
+). 
 
 
 
[4-{3-(4-Methoxyphenyl)-2-[(4-methoxyphenyl)imino]-1-methylimidazolidin-4-
ylmethyl}phenyl](phenyl)methanone hydrochloride (2-11): The general procedure was 
employed for the coupling of 2-4 (54 mg, 0.15 mmol) and 4-iodobenzophenone (69 mg, 0.23 
mmol) using a catalyst composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 
0.012 mmol). This procedure afforded 56 mg (69%) of the title compound as a pale yellow-brown 
foam solid: mp = 70–71 ºC. 1H NMR (500 MHz, CDCl3)  8.75 (s, 1 H), 7.73 (d, J = 8.0 Hz, 2 H), 
7.67 (d, J = 7.0 Hz, 2 H), 7.59 (t, J = 8.0 Hz, 1 H), 7.48 (t, J = 7.5 Hz, 2 H), 7.30 (d, J = 8.5 Hz, 2 
H), 7.20 (d, 7.5 Hz, 2 H), 7.15 (d, J = 8.0 Hz, 2 H), 6.67 (d, J = 7.5 Hz, 2 H), 6.57 (d, J = 7.5 Hz, 
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2 H), 4.72–4.65 (m, 1 H), 4.02–3.98 (m, 1 H), 3.76–3.73 (m, 1 H), 3.70 (s, 3 H), 3.65 (s, 3 H), 3.23 
(s, 3 H), 3.21–3.17 (m, 1 H), 3.10 (dd, J = 4.5, 13.5 Hz, 1 H); 13C NMR (125 MHz, CDCl3)  
196.2, 159.5, 158.3, 156.1, 140.2, 137.3, 136.3, 132.6, 130.5, 129.9, 129.5, 129.2, 128.3, 128.2, 
128.0, 126.6, 114.8, 113.9, 63.1, 55.6, 55.5, 54.4, 38.8, 36.1; IR (film) 3135, 1655, 1630 cm–1. MS 
(ESI) 506.2437 (506.2438 calcd for C32H32N3O3, M
+). 
 
 
4-(Benzo[d][1,3]dioxol-5-ylmethyl)-N,3-bis(4-methoxyphenyl)-1-methylimidazolidin-2-
imine hydrochloride (2-12): The general procedure was employed for the coupling of 2-4 (54 
mg, 0.15 mmol) and 4-bromo-1,2-(methylenedioxy)benzene (27 µL, 0.23 mmol) using a catalyst 
composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This 
procedure afforded 59 mg (81%) of the title compound as a pale yellow-brown foam solid: mp = 
66–68 ºC. 1H NMR (700 MHz, CDCl3)  7.01 (d, J = 9.1 Hz, 2 H), 6.92 (d, J = 9.1 Hz, 2 H), 6.73 
(d, J = 7.7 Hz, 1 H), 6.61–6.58 (m, 4 H), 6.51 (d, J = 9.1 Hz, 2 H), 5.93 (s, 2 H), 4.31–4.26 (m, 1 
H), 3.84–3.81 (m, 1 H), 3.70 (s, 3 H), 3.65 (s, 3 H), 3.53 (dd, J = 7.0, 9.8 Hz, 1 H), 3.39 (s, 3 H), 
2.95 (dd, J = 4.2, 13.3 Hz, 1 H), 3.78 (dd, J = 9.8, 14.0 Hz, 1 H); 13C NMR (175 MHz, CDCl3)  
159.1, 157.7, 156.4, 148.1, 146.8, 129.6, 128.7, 128.4, 127.8, 126.8, 122.2, 114.5, 113.7, 109.2, 
108.6, 101.1, 63.9, 55.5, 55.4, 53.8, 38.9, 35.6; IR (film) 3005, 1640 cm–1. MS (ESI) 446.2077 
(446.2074 calcd for C26H28N3O4, M
+). 
 
 
 
4-[(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl]-N,3-bis(4-methoxyphenyl)-1-
methylimidazolidin-2-imine hydrochloride (2-13): The general procedure was employed for the 
coupling of 2-4 (54 mg, 0.15 mmol) and 6-bromo-1,4-benzodioxane (30 µL, 0.225 mmol) using a 
catalyst composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This 
procedure afforded 67 mg (90%) of the title compound as a pale yellow-brown foam solid: mp = 
76–77 ºC. 1H NMR (500 MHz, CDCl3)  6.95 (d, J = 9.0 Hz, 2 H), 6.88 (d, J = 9.0 Hz, 2 H), 6.78 
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(d, J = 8.0 Hz, 1 H), 6.61–6.57 (m, 4 H), 6.49 (d, J = 8.5 Hz, 2 H), 4.29–4.24 (m, 1 H), 4.23 (s, 4 
H), 3.84–3.80 (m, 1 H), 3.69 (s, 3 H), 3.64 (s, 3 H), 3.49 (dd, J = 7.0, 10.5 Hz, 1 H), 3.39 (s, 3 H), 
2.92 (dd, J = 4.5, 13.5 Hz, 1 H), 2.72 (dd, J = 9.5, 14.0 Hz, 1 H); 13C NMR (125 MHz, CDCl3)  
159.0, 157.5, 156.4, 143.7, 142.9, 129.9, 128.5, 128.3, 127.9, 126.5, 122.0, 117.7, 117.7, 114.5, 
113.7, 64.4, 64.3, 63.9, 55.5, 55.4, 53.7, 38.5, 35.3; IR (film) 3000, 1639 cm–1. MS (ESI) 460.2226 
(460.2231 calcd for C27H30N3O4, M
+). 
 
 
 
N,3-Bis(4-methoxyphenyl)-1-methyl-4-(2-methylbenzyl)imidazolidin-2-imine hydrochloride 
(2-14): The general procedure was employed for the coupling of 2-4 (54 mg, 0.15 mmol) and 2-
bromotoluene (27 µL, 0.23 mmol) using a catalyst composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), 
and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 52 mg (76%) of the title compound 
as a pale yellow-brown foam solid. The material contained ca. 8% of an unsaturated cyclic 
guanidine resulting from oxidation of the title compound (tentatively assigned as the 2-
aminoimidazole derivative (E)-N,3-bis(4-methoxyphenyl)-1-methyl-4-(2-methylbenzyl)-1,3-
dihydro-2H-imidazol-2-imine hydrochloride). mp = 78–79 ºC. 1H NMR (700 MHz, CDCl3)  
7.15–7.11 (m, 3 H), 7.08–7.07 (m, 1 H), 7.00 (d, J = 9.1 Hz, 2 H), 6.90 (d, J = 8.4 Hz, 2 H), 6.60 
(d, J = 9.1 Hz, 2 H), 6.49 (d, J = 9.1 Hz, 2 H), 4.33–4.29 (m, 1 H), 3.81–3.78 (m, 1 H), 3.69 (s, 3 
H), 3.64 (s, 3 H), 3.54 (dd, J = 7.7, 10.5 Hz, 1 H), 3.42 (s, 3 H), 3.06 (dd, J = 4.2, 14.0 Hz, 1 H), 
2.81 (dd, J = 10.5, 14.0 Hz, 1 H), 2.10 (s, 3 H); 13C NMR (175 MHz, CDCl3)  159.0, 157.5, 156.4, 
136.3, 133.4, 130.8, 129.6, 129.6, 128.6, 128.2, 127.5, 126.6, 126.4, 114.5, 113.7, 62.6, 55.5, 55.4, 
54.1, 36.8, 35.5, 19.3; IR (film) 3002, 1630 cm–1. MS (ESI) 416.2328 (416.2333 calcd for 
C26H30N3O2, M
+). 
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1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine 
hydrochloride (2-15): The general procedure was employed for the coupling of 2-5 (59 mg, 0.15 
mmol) and 4-bromotoluene (35 mg, 0.23 mmol) using a catalyst composed of Pd2(dba)3 (2.7 mg, 
0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 71 mg (99%) of the 
title compound as a pale yellow-brown foam solid: mp = 61–62 ºC. 1H NMR (500 MHz, CDCl3)  
7.18 (d, J = 8.0 Hz, 2 H), 7.11 (d, J = 8.0 Hz, 2 H), 6.90–6.87 (m, 4 H), 6.61 (d, J = 8.5 Hz, 2 H), 
6.50 (d, J = 8.5 Hz, 2 H), 4.02–3.95 (m, 1 H), 3.87–3.80 (m, 2 H), 3.70 (s, 3 H), 3.65 (s, 3 H), 3.35 
(d, J = 10.5 Hz, 1 H), 2.98 (d, J = 13.5 Hz, 1 H), 2.75 (d, J = 13.5 Hz, 1 H), 2.36 (s, 3 H), 1.26–
1.20 (m, 6 H); 13C NMR (125 MHz, CDCl3)  159.2, 157.3, 155.2, 137.6, 131.5, 130.2, 130.0, 
129.5, 128.7, 127.0, 126.2, 114.3, 113.7, 65.7, 55.9, 55.5, 55.5, 45.1, 42.0, 25.3, 21.1, 12.3; IR 
(film) 2971, 1630 cm–1. MS (ESI) 444.2645 (444.2646 calcd for C28H34N3O2, M
+). 
 
 
 
(+)-1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine 
hydrochloride (2-15; prepared using (S)-Phanephos as ligand): The general procedure for the 
asymmetric synthesis of cyclic guanidine products was employed for the coupling of 2-5 (58.5 mg, 
0.15 mmol) and 4-bromotoluene (39 mg, 0.225 mmol) using a catalyst composed of Pd2(dba)3 (2.7 
mg, 0.003 mmol), and (S)-Phanephos (6.9 mg, 0.012 mmol) except the reaction was run for 36 hrs 
in order to ensure complete conversion. This procedure afforded 65.0 mg (84%) of the title 
compound as a pale yellow-brown foam solid: [α]23D +18.0 (c 1.3, CH2Cl2). Spectroscopic data 
were identical to those provided above. The enantiomeric purity was determined to be 61:39 er as 
assessed by converting this compound to the corresponding Mosher amide (see below for details). 
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(+)-1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine 
hydrochloride (2-15; prepared using (S)-BINAP as ligand): The general procedure for the 
asymmetric synthesis of cyclic guanidine products was employed for the coupling of 2-5 (39 mg, 
0.1 mmol) and 4-bromotoluene (26 mg, 0.15 mmol) using a catalyst composed of Pd2(dba)3 (1.8 
mg, 0.002 mmol), and (S)-BINAP (5.0 mg, 0.008 mmol). This procedure afforded 48 mg (99%) 
of the title compound as a pale yellow-brown foam solid: [α]23D -5.9 (c 0.9, CH2Cl2). Spectroscopic 
data were identical to those provided above. The enantiomeric purity was determined to be 48:52 
er as assessed by converting this compound to the corresponding Mosher amide (see below for 
details). 
 
 
4-(Benzo[d][1,3]dioxol-5-ylmethyl)-1-ethyl-N,3-bis(4-methoxyphenyl)-4-
methylimidazolidin-2-imine hydrochloride (2-16): The general procedure was employed for the 
coupling of 2-5 (59 mg, 0.15 mmol) and 4-bromo-1,2-(methylenedioxy)benzene (27 µL, 0.225 
mmol), using a catalyst composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), and Nixantphos (6.6 mg, 
0.012 mmol). This procedure afforded 76 mg (99%) of the title compound as a pale yellow-brown 
foam solid: mp = 66–67 ºC. 1H NMR (500 MHz, CDCl3)  6.93–6.83 (m, 4 H), 6.81 (d, J = 8.0 Hz, 
1 H), 6.71–6.68 (m, 2 H), 6.62 (s, br, 2 H), 6.51 (d, J = 8.5 Hz, 2 H), 5.98 (s, 2 H), 4.01–3.94 (m, 
1 H), 3.88 (d, J = 10.0 Hz, 1 H), 3.84–3.77 (m, 1 H), 3.71 (s, 3 H), 3.66 (s, 3 H), 3.42 (d, J = 10.5 
Hz, 1 H), 2.96 (d, J = 13.5 Hz, 1 H), 2.69 (d, J = 13.5 Hz, 1 H), 1.26–1.19 (m, 6 H); 13C NMR 
(125 MHz, CDCl3)  159.3, 157.6, 155.3, 148.0, 147.2, 129.8, 128.1, 128.0, 126.7, 126.7, 123.6, 
114.4, 113.7, 110.4, 108.5, 101.3, 65.8, 55.9, 55.5, 55.5, 45.0, 42.1, 25.3, 12.3; IR (film) 2972, 
1627 cm–1. MS (ESI) 474.2379 (474.2387 calcd for C28H32N3O4, M
+). 
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1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(thiophen-2-ylmethyl)imidazolidin-2-imine 
hydrochloride (2-17): The general procedure was employed for the coupling of 2-5 (59 mg, 0.15 
mmol) and 2-bromothiophene (22 µL, 0.225 mmol), using a catalyst composed of Pd2(dba)3 (2.7 
mg, 0.003 mmol), and Nixantphos (6.6 mg, 0.012 mmol). This procedure afforded 70 mg (99%) 
of the title compound as a pale yellow-brown foam solid: mp = 63–65 ºC. 1H NMR (500 MHz, 
CDCl3) δ 7.31–7.30 (m, 1 H), 7.06–6.97 (m, 6 H), 6.62 (d, J = 8.5 Hz, 2 H), 6.49 (d, J = 9.5 Hz, 2 
H), 3.98–3.87 (m, 2 H), 3.69–3.60 (m, 8 H), 3.24 (d, J = 15.5 Hz, 1 H), 3.05 (d, J = 15.0 Hz, 1 H), 
1.27 (s, 3 H), 1.10 (t, J = 7.5 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 159.3, 157.4, 155.2, 136.3, 
130.3, 128.4, 128.1, 127.2, 126.7, 126.4, 125.5, 114.4, 113.7, 65.3, 55.9, 55.5, 55.4, 41.9, 39.9, 
26.0, 11.9; IR (film) 3041, 1630 cm–1. MS (ESI) 436.2057 (436.2053 calcd for C25H29N3O2S, M
+). 
 
 
 
(Z)-1-Ethyl-N,3-bis(4-methoxyphenyl)-4-methyl-4-(pent-2-en-1-yl)imidazolidin-2-imine 
hydrochloride (2-18): The general procedure (using modified stoichiometries of reactants) was 
used for the coupling of 2-5 (59 mg, 0.15 mmol) and 1-bromobutene (300 µL, 0.60 mmol, 4.0 
equiv, 2 M solution in toluene) using a catalyst composed of Pd2(dba)3 (2.7 mg, 0.003 mmol), and 
Nixantphos (6.6 mg, 0.012 mmol) in the presence of NaOtBu (64.9 mg, 0.60 mmol, 4.5 equiv). 
This procedure afforded 57 mg (86%) of the title compound as a pale yellow-brown foam. 1H 
NMR (700 MHz, CDCl3)  6.99 (s, br, 1 H), 6.92 (d, J = 8.4 Hz, 2 H), 6.76 (s, br, 1 H), 6.65–6.53 
(m, br, 2 H), 6.49 (d, J = 9.1 Hz, 2 H), 5.74–5.70 (m, 1 H), 5.39–5.35 (m, 1 H), 4.10–4.05 (m, 1 
H), 3.92–3.86 (m, 1 H), 3.71–3.67 (m, 1 H), 3.68 (s, 3 H), 3.64 (s, 3 H), 3.59 (d, J = 9.8 Hz, 1 H), 
2.42 (dd, J = 6.3, 14.7 Hz, 1 H), 2.28 (dd, J = 7.7, 15.4 Hz, 1 H), 2.10–2.06 (m, 2 H), 1.34 (t, J = 
7.0 Hz, 3 H), 1.25 (s, 3 H), 1.01 (t, J = 7.7 Hz, 3 H); 13C NMR (175 MHz, CDCl3)  159.2, 157.3, 
155.0, 137.3, 130.5, 129.7, 128.1, 126.3, 120.7, 114.2, 113.7, 65.3, 56.2, 55.4, 55.4, 42.2, 37.1, 
25.6, 21.0, 13.9, 12.3; IR (film) 3006, 1627 cm–1. MS (ESI) 408.2643 (408.2646 calcd for 
C25H34N3O2, M
+).  
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(±)-(S*,S*)-N,3-Bis(4-methoxyphenyl)-1-methyl-4-(phenyl(p-tolyl)methyl)imidazolidin-2-
imine hydrochloride (2-19a). The general procedure was employed for the coupling of 2-6a (132 
mg, 0.3 mmol) and 4-bromotoluene (76 mg, 0.45 mmol), using a catalyst composed of Pd2(dba)3 
(5.5 mg, 0.006 mmol), and Nixantphos (13.2 mg, 0.024 mmol). This procedure afforded 35 mg 
(22%) of the title compound as a pale yellow-brown solid: mp = 91–93 ºC. This compound was 
judged to be a single diastereomer (> 20:1 dr) by 1H NMR analysis. 1H NMR (700 MHz, CDCl3) 
 11.33 (s, br, 1 H), 7.38–7.36 (m, 2 H), 7.31–7.29 (m, 1 H), 7.25–7.24 (m, 2 H), 7.04 (d, J = 7.7 
Hz, 2 H), 6.99 (d, J = 8.4 Hz, 2 H), 6.76 (d, J = 9.1 Hz, 2 H), 6.46 (d, J = 9.1 Hz, 2 H), 6.40 (s, 4 
H), 4.65–4.62 (m, 1 H), 4.35 (d, J = 8.4 Hz, 1 H), 4.15–4.12 (m, 1 H), 3.64 (s, 3 H), 3.63 (s, 3 H), 
3.51 (dd, J = 4.9, 11.2 Hz, 1 H), 3.27 (s, 3 H), 2.28 (s, 3 H); 13C NMR (175 MHz, CDCl3)  158.9, 
158.1, 157.7, 139.3, 137.3, 136.6, 132.0, 129.6, 129.2, 128.6, 128.5, 128.2, 128.2, 127.9, 126.3, 
114.1, 113.7, 66.7, 55.4, 54.8, 53.3, 35.2, 21.0 (one carbon signal is absent due to incidental 
equivalence); IR (film) 3105, 1641 cm–1. MS (ESI) 492.2652 (492.2646 calcd for C32H34N3O2, 
M+). 
 
 
 
(±)-N,2,Bis-(4-methoxyphenyl)-1-(4-methylbenzyl)tetrahydro-1H-pyrrolo[1,2-c]imidazol-
3(2H)-imine hydrochloride (2-20). The general procedure was employed for the coupling of 2-7 
(77.6 mg, 0.2 mmol) and 4-bromotoluene (52 mg, 0.3 mmol), using a catalyst composed of 
Pd2(dba)3 (3.6 mg, 0.004 mmol), and Nixantphos (8.8 mg, 0.016 mmol). This procedure afforded 
53 mg (60%) of the title compound as a pale brown solid and as a 1.5:1 mixture of diastereomers 
as determined by 1H NMR analysis. The data is for the mixture except the 1H NMR data, which is 
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only for the major isomer. Mp = 58–61 ºC. 1H NMR (700 MHz, CDCl3)  10.94, (s, br, 1 H), 7.21–
7.14 (m, 4 H), 7.12–7.08 (m, 2 H), 6.97 (d, J = 8.4 Hz, 2 H), 6.84–6.80 (m, 2 H), 6.68–6.67 (m, 2 
H), 4.50–4.47 (m, 1 H), 3.95–3.92 (m, 1 H), 3.77 (s, 3 H), 3.71 (s, 3 H), 3.45–3.44 (m, 1 H), 3.35–
3.32 (m, br, 1 H), 2.98 (dd, J = 3.5, 13.3 Hz, 1 H), 2.53 (dd, J = 11.2, 14.0 Hz, 1 H), 2.31 (s, 3 H), 
2.07–2.03 (m, 1 H), 1.87–1.79 (m, 1 H), 1.62–1.58 (m, 2 H); 13C NMR (175 MHz, CDCl3)  159.6, 
159.5, 157.8, 157.7, 137.0, 136.8, 132.4, 131.7, 129.7, 129.5, 129.4, 128.8, 128.4, 128.0, 126.6, 
126.0, 125.4, 115.1, 115.1, 114.1, 68.4, 66.2, 64.9, 64.6, 55.5, 55.4, 49.3, 48.7, 38.2, 35.2, 31.2, 
26.7, 26.2, 25.8, 21.0, 20.0; IR (film) 1625 cm–1. MS (ESI) 442.2484 (442.2489 calcd for 
C28H32N3O2, M
+). 
 
 
Deprotection of Cyclic Guanidine Product 18 
 
 
 
1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine 
hydrochloride (2-21). A Schlenk tube was charged with a stirbar, 2-15 (48 mg, 0.1 mmol) and 
CH3CN (1 mL). A solution of ceric ammonium nitrate (329 mg, 0.6 mmol) in H2O (6 mL) was 
added to the reaction flask and the mixture was stirred at rt for 5 min. The mixture was then heated 
at 50 oC for 12 h before being cooled to rt, at which time dichloromethane (15 mL) was added. 
The mixture was transferred to a separatory funnel and the layers were separated. The organic 
layer was washed with saturated Na2SO3 (10 mL), saturated aqueous NaHCO3 (10 mL), and brine 
(10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo. The crude material was purified by flash chromatography on silica gel to afford 14.6 mg 
(39%) of the title compound as white solid: mp = 223–226 ºC. 1H NMR (700 MHz, CDCl3) δ 7.19 
(s, br 2 H), 7.13 (d, J = 7.7 Hz, 2 H), 7.03 (d, J = 9.1 Hz, 2 H), 6.98 (d, J = 7.7 Hz, 2 H), 3.91–3.88 
(m, 1 H), 3.88 (s, 3 H), 3.84–3.81 (m, 1 H), 3.77 (d, J = 9.8 Hz, 1 H), 3.18 (d, J = 9.8 Hz, 1 H), 
2.94 (d, J = 13.3 Hz, 1 H), 2.70 (d, J = 13.3 Hz, 1 H), 2.33 (s, 3 H), 1.31 (s, 3 H)1.25 (t, J = 7.0 
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Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ 161.1, 155.9, 137.5, 131.4 (br, 1 C), 131.3, 129.9, 129.6, 
123.5, 115.8, 65.8, 55.7, 55.6, 43.7, 41.3, 23.9, 21.0, 12.2; IR (film) 3250, 1658 cm–1. MS (ESI) 
338.2228 (338.2227 calcd for C21H28N3O, M
+). 
 
Structural Assignment of Deprotected Cyclic Guanidine Product 2-21. 
 
 
 
  
 
1-Ethyl-3-(4-methoxyphenyl)-1-(2-methylallyl)urea (S2). A flame-dried flask equipped with a 
stirbar was charged with N-ethyl-2-methylallylamine (1.3 mL, 10 mmol) and dichloromethane 
(100 mL). 4-methoxyphenyl isocyanate (1.55 mL, 12 mmol) was added to the flask and the mixture 
was stirred at rt for 1 h. The crude reaction mixture was concentrated in vacuo and purified by 
flash chromatography on silica gel to afford 2.43 mg (98%) of the title compound as a pale yellow 
oil. 1H NMR (500 MHz, CDCl3) δ 7.23 (d, J = 8.5 Hz, 2 H), 6.82 (d, J = 8.5 Hz, 2 H), 6.30, (s, 1 
H), 5.02 (s, br, 2 H), 3.83 (s, br, 2 H), 3.77 (s, 3 H), 3.42 (q, J = 7.0 Hz, 2 H), 1.79 (s, 3 H), 1.20 
(t, J = 7.0 Hz, 3 H).  
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1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-one (S3): A flame-
dried Schlenk tube was cooled under vacuum and charged with Pd2(dba)3 (110 mg, 0.12 mmol), 
xantphos (139 mg, 0.24 mmol), NaOtBu (865 mg, 9.0 mmol), and 4-bromotoluene (1.5 g, 9.0 
mmol). A solution of S2 (1.5 g, 6.0 mmol) in toluene (30 mL) was added via syringe and the tube 
was heated to 105 oC for 3 h. The mixture was cooled to rt and saturated aqueous NH4Cl (15 mL) 
and ethyl acetate (25 mL) were added. The layers were separated and the organic layer was dried 
over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was 
purified by flash chromatography on silica gel to afford 1.96 mg (97%) of the title compound as 
an orange yellow oil. 1H NMR (700 MHz, CDCl3) δ 7.18 (d, J = 9.1 Hz, 2 H), 7.08 (d, J = 7.7 Hz, 
2 H), 6.99 (d, J = 8.4 Hz, 2 H), 6.92 (d, J = 9.1 Hz, 2 H), 3.82 (s, 3 H), 3.46 (d, J = 8.4 Hz, 1 H), 
3.37–3.32 (m, 1 H), 3.27–3.22 (m, 1 H), 2.92 (d, J = 13.3 Hz, 1 H), 2.84 (d, J = 9.1 Hz, 1 H), 2.65 
(d, J = 13.3 Hz, 1 H), 2.31 (s, 3 H), 1.22 (s, 3 H), 1.11 (t, J = 7.0 Hz, 3 H). 
 
 
 
 
1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-imine 
hydrochloride (2-21). A flame-dried flask was cooled under a stream of N2 and charged with S3 
(100 mg, 0.3 mmol) and toluene (2 mL). POCl3 (0.6 mL) was added and the mixture was stirred 
at 100 oC until the starting material had been consumed as judged by ESI+ MS analysis (ca. 2 hr). 
The reaction mixture was cooled to rt and concentrated in vacuo. The crude product was dissolved 
in acetonitrile (10 mL) and a solution of ammonia in ethanol (15 mL, 2 M in ethanol) was added. 
The mixture was stirred at rt until the starting material had been consumed as judged by ESI+ MS 
analysis (ca. 1 hr). The reaction mixture was concentrated and dissolved in dichloromethane (5 
mL). Water (5 mL) was added and the mixture was transferred to a separatory funnel. The layers 
were separated and the organic layer was washed with 1 M HCl (10 mL) and saturated aqueous 
sodium chloride (2 x 10 mL). The combined aqueous layers were extracted with dichloromethane 
(3 x 10 mL). The combined organics layers were dried over anhydrous sodium sulfate, filtered, 
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and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel 
to afford 70 mg (63%) of the title compound as a white solid. The spectroscopic properties of this 
compound were identical to that of compound 2-21 described above that was prepared by 
deprotection of 2-15. 
 
 
Stereochemical Analysis of Enantioenriched Cyclic Guanidine Product 2-15.  
In order to assess the enantiomeric purity of cyclic guanidine products 2-15 prepared from (S)-
Phanephos and (S)-BINAP, the carboamination products were converted to the corresponding 
Mosher amides S4 via the two-step procedure illustrated below. The enantiomeric ratio of 2-15 
was assigned based on the diastereomeric ratio of crude S4 as determined by 1H NMR analysis. 
 
  
  
 
 
 
(2R)-N-(1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-ylidene)- 
3,3,3-trifluoro-2-methoxy-2-phenylpropanamide hydrochloride (S4 prepared from (+)-2-15 
that was generated using (S)-Phanephos as ligand). The chiral guanidine (+)-18 prepared using 
(S)-Phanephos as the ligand (51.5 mg, 0.11 mmol) was deprotected with ceric ammonium nitrate 
(361 mg, 0.66 mmol) according to the procedure detailed above. After flash chromatography, this 
procedure afforded 8.0 mg (20%) of enantioenriched 2-21 as a brown solid. The spectroscopic 
properties of this compound were identical to that of racemic 2-21 described above. The purified 
nonracemic material 27 (8.0 mg, 0.02 mmol) was dissolved in dichloromethane (1 mL) and stirred 
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at rt. NaH (2.5 mg, 0.06 mmol, 60% dispersion in mineral oil) was added and the mixture was 
allowed to stir at rt for 10 min. Neat (S)-(+)-α-Methoxy-α-trifluoromethylphenylacetyl chloride (6 
µL, 0.03 mmol) was added via syringe and the mixture was stirred at rt until the starting material 
had been consumed as judged by ESI+ MS analysis of an aliquot removed from the reaction mixture 
(ca. 1 hr). Brine (2 mL) was added and the biphasic mixture was transferred to a separatory funnel. 
The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 4 mL). 
The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated 
in vacuo. This procedure afforded a crude mixture that was determined to be a 61:39 mixture of 
diastereomers by 1H NMR analysis. The crude material was purified by flash chromatography on 
silica gel to afford 8.9 mg (77%) of the title compound as a pale brown foamy-oil and as a 57:43 
mixture of diastereomers (note that product er was assigned based on dr of the crude product, as 
some separation of diastereomers likely occurred during purification). Data are for the mixture of 
isomers. 1H NMR (500 MHz, CDCl3) δ 7.44–7.40 (m, 3.5 H), 7.29–7.24 (m, 3.75 H), 7.23–7.16 
(m, 5 H), 7.12–7.10 (m, 3.5 H), 7.05–7.02 (m, 3.5 H), 6.89–6.87 (m, 3.5 H), 3.83 (s, 5.25 H), 3.77 
(d, J = 10.0 Hz, 0.75 H), 3.73 (d, J = 10.0 Hz, 1 H), 3.35–3.25 (m, 2.75 H), 3.24 (s, 3 H), 3.22 (s, 
2.25 H), 3.20–3.18 (m, 0.75 H), 3.16 (d, J = 10.0 Hz, 1 H), 3.10 (d, J = 10.5 Hz, 0.75 H), 3.07–
3.03 (m, 1.75 H), 2.75 (d, J = 13.5 Hz, 1 H), 2.69 (d, J = 13.5 Hz, 0.75 H), 2.32 (s, 5.25 H), 1.31 
(s, 2.25 H), 1.28 (s, 3 H), 1.12–1.08 (m, 5.25 H); 13C NMR (125 MHz, CDCl3) δ 167.9, 167.8, 
164.4, 164.3, 159.7, 159.6, 136.9, 136.9, 135.8, 135.7, 132.2, 132.2, 131.6, 131.6, 130.2, 130.1, 
129.3, 129.3, 127.9, 127.6, 127.5, 127.5, 127.4, 125.7, 123.4, 114.1, 64.5, 64.5, 55.5, 55.0, 54.7, 
54.3, 44.3, 43.9, 40.2, 40.1, 24.5, 24.4, 21.0, 12.4, 12.3; 19F NMR (376 MHz, CDCl3) δ –69.56, –
69.58; IR (film) 2925, 1653, 1559 cm–1. MS (ESI) 554.2625 (554.2625 calcd for C31H34F3N3O3, 
M+.
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(2R)-N-(1-Ethyl-3-(4-methoxyphenyl)-4-methyl-4-(4-methylbenzyl)imidazolidin-2-ylidene)-
3,3,3-trifluoro-2-methoxy-2-phenylpropanamide hydrochloride (S4 prepared from (–)-2-15 
that was generated using (S)-BINAP as ligand). The chiral guanidine (–)-2-15 prepared using 
(S)-BINAP as the ligand (48 mg, 0.1 mmol) was deprotected with ceric ammonium nitrate (329 
mg, 0.6 mmol) according to the procedure detailed above. After flash chromatography, this 
procedure afforded 14.4 mg (39%) of enantioenriched 2-21 as a brown solid. The spectroscopic 
properties of this compound were identical to that of compound racemic 2-21 described above. 
The purified nonracemic material 27 (14.4 mg, 0.04 mmol) was dissolved in dichloromethane (1 
mL) and stirred at rt. NaH (4.8 mg, 0.12 mmol, 60% dispersion in mineral oil) was added and the 
mixture was allowed to stir at rt for 10 min. Neat (S)-(+)-α-Methoxy-α-
trifluoromethylphenylacetyl chloride (11 µL, 0.06 mmol) was added via syringe and the mixture 
was stirred at rt until the starting material had been consumed as judged by ESI+MS analysis of an 
aliquot removed from the reaction mixture (ca. 1 hr). Brine (2 mL) was added and the biphasic 
mixture was transferred to a separatory funnel. The layers were separated and the aqueous layer 
was extracted with dichloromethane (2 x 4 mL). The combined organic layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. This procedure afforded a crude 
mixture that was determined to be a 48:52 mixture of diastereomers by 1H NMR analysis. The 
crude material was purified by flash chromatography on silica gel to afford 10.8 mg (48%) of the 
title compound as a pale brown foamy-oil and as a 51:49 mixture of diastereomers. Spectroscopic 
data were identical to those described above (although integration ratios differed due to the 
differences in product distribution. 
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Chapter 3 
Synthesis of 2-Aminoimidazoles via Pd-Catalyzed Alkyne Carboamination 
Reactions and Applications to Natural Product Synthesis 
3.1 Introduction 
 As detailed in Chapter 1, the unsaturated cyclic guanidine structural motif is ubiquitous in 
many biologically active natural products (see Figure 1.1).1–7,9,11–15,54,55 As such, many research 
groups have developed elegant syntheses that can rapidly and efficiently fashion these products 
from commercially available sources.9,10,12,14,15,42 However, none of these routes accommodate late 
stage derivatization of the targeted product.  For this reason, we set out to develop a methodology 
that has the ability to create libraries of analogues from a simple, easily accessible substrate. 
 
3.2 Optimization of Reaction Conditions 
In light of the deprotection issues of bis-PMP protected substrates found in chapter 2, along 
with the lack of stability of bis-Boc protected substrate 2-3, we targeted a new series of substrates. 
As such, the mono-protected N-tosyl guanidine 3-1 was constructed. To our delight, 3-1 was 
smoothly converted to the unsaturated carboamination product 3-3 by using a variety of different 
Buchwald ligands (Table 3.1, entries 1-4).  The monodentate ligand RuPhos (entry 2) afforded the 
desired product in the highest yield.  
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Table 3.1 Optimization of Ligand Choicea 
 
 
 
 
 
 
 
 
 
 
Entry Ligand Yield (%)b 
1 
2 
3 
4 
 
CPhos 
RuPhos 
BrettPhos 
tBuDavePhos 
(80) 
(81) 80 
 (45) 
 (41) 
a Conditions: 1.0 equiv of guanidine substrate, 1.2 equiv of 3-2, 2.4 equiv of LiOtBu, 4 mol % Pd(OAc)2, 8 mol 
% ligand, trifluorotoluene (0.1 M), 100 °C, reactions run for 3 h. b Isolated yields. Numbers in parentheses are NMR 
yields based on phenanthrene as an internal standard. 
 
3.3 Examination of Scope  
With optimized conditions in hand, the scope of these Pd-catalyzed carboamination 
transformations was analyzed by coupling 3-1 with a variety of aryl triflates (Table 3.2). 
Gratifyingly, aryl triflates bearing electron-donating, electron-neutral, and electron-withdrawing 
groups (entries 1-5) afforded the corresponding unsaturated cyclic guanidine in good yields. 
However, coupling substrate 3-1 with 4-benzoylphenyl trifluoromethanesulfonate required a 
shorter reaction time in order to prevent conversion to the desilylated product (entry 5). Another 
issue regarding electron poor aryl triflates is decomposition of the triflate to the corresponding 
alcohol, which was solved by using 2 equivalents of the aryl triflate. Additionally, the use of an 
ortho substituted aryl triflate underwent smooth conversion to the desired carboamination product 
(entry 4).  
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Table 3.2 Scope of Carboamination Reactiona 
 
 
 
 
 
Entry Product Yield (%)b 
 
 
1c 
 
 
 
 
 
 
2c 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
4 
 
 
 
 
 
 
5d 
 
 
 
 
  
 
81 
 
 
 
 
 
 
85 
 
 
 
 
 
 
 
82 
 
 
 
 
 
 
78 
 
 
 
 
 
 
95 
a Conditions: 1.0 equiv of guanidine substrate, 2.0 equiv R1– OTf, 2.4 equiv of LiOtBu, 4 mol % Pd(OAc)2, 8 
mol % RuPhos, trifluorotoluene (0.1 M), reactions run overnight. b Isolated yields. c This reaction ran for 3 h and 
was conducted using 1.2 equiv of R1– OTf. d Reaction was run for 30 min. 
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3.4 Application to Total Synthesis 
To showcase the utility of this carboamination reaction, it was employed as a key step in the 
synthesis of preclathridine A. The tertiary amine 3-8 was efficiently prepared from commercially 
available reagents, following a procedure from Looper and coworkers.22 This molecule was then 
deprotected and coupled to afford the pseudothiourea 3-9 in good yield. Careful selection of metal 
and reaction temperature were necessary to produce guanidine 3-1 without generation of the 
undesirable 2-aminoimidazole side product, formed via hydroamination. The carboamination 
reaction of 3-1 proceeded smoothly, followed by an acidic workup to afford the desilylated cyclic 
guanidine 3-10. Deprotection of N-tosyl resulted in the synthesis of preclathridine A, in 6 steps 
and 25% overall yield. This strategy allows for the rapid functionalization of a late stage 
intermediate, an approach that can readily access analogues of the biologically active natural 
product from an easily accessible substrate that has been made on gram scale.  
 
Scheme 3.1 Total synthesis of preclathridine A 
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3.5 Conclusion 
In conclusion, we have developed a new method for the construction of unsaturated 5-
membered cyclic guanidines. The carboamination reactions proceed in good yields (78-95%) and 
tolerates a wide variety of aryl triflates. Additionally, this reaction was employed in the highly 
flexible synthesis of preclathridine A. Further studies are aimed at examining the substrate scope, 
as well as the synthesis of more 2-aminoimidazole containing natural products.  
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3.6 Experimental 
 
General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware 
unless otherwise noted. Palladium acetate and ligands used in this section were purchased from 
Strem Chemical Co. and used without purification. Aryl triflates were prepared according to a 
procedure published by Frantz and coworkers,56 followed by additional purification by column 
chromatography. All other reagents were obtained from commercial sources and were used as 
obtained unless otherwise noted. Lithium tert-butoxide was kept in a glove box and removed only 
prior to use. Toluene, THF, diethyl ether and dichloromethane were purified using a GlassContour 
solvent purification system. Trifluorotoluene was purified by distillation under N2 prior to use. 
Yields refer to isolated yields of compounds estimated to be ≥95% pure as determined by 1H NMR 
analysis unless otherwise noted. 
 
Preparation and Characterization of Guanidine Substrate 3-2 
 
 
 
N-methyl-N-(3-(trimethylsilyl)prop-2-yn-1-yl)prop-2-en-1-amine (3-8).  The title compound 
was prepared using the general procedure reported by Looper.22 A flame-dried flask equipped with 
a stirbar was cooled under a stream of N2, and charged with acetonitrile (78 mL), N-
methylallylamine (1.5 mL, 15.6 mmol), formaldehyde (3 mL, 69 mmol, 37% solution in water), 
ethynyltrimethylsilane (1.67 mL, 11.7 mmol), and copper (I) bromide (224 mg, 1.56 mmol). The 
resulting reaction mixture was stirred overnight (16 h) at rt, and had turned to a pale green solution. 
The solution was then concentrated in vacuo to afford the crude product, which was then dissolved 
in diethyl ether (15 mL). The mixture was filtered through a plug of celite, and the celite was 
washed with 200 mL of dichloromethane. The filtrate was transferred to a separatory funnel, and 
1 M NaOH (60 mL) was added to the separatory funnel. The layers were separated, and the organic 
layer was extracted. The organic layer was washed with 1 M NaOH (2 x 60 mL), then dried over 
anhydrous sodium sulfate. The crude product concentrated in vacuo, and was purified by flash 
chromatography on silica gel to afford 1.91 g (90%) of the title compound as a clear and colorless 
oil: 1H NMR (500 MHz, CDCl3) δ 5.87–5.79 (m, 1 H), 5.21 (d, J = 17 Hz, 1 H), 5.15 (d, J = 10 
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Hz, 1 H), 3.31 (s, 2 H), 3.04 (d, J = 7 Hz, 2 H), 2.29 (s, 3 H), 0.17 (s, 9 H); 13C NMR (125 MHz, 
CDCl3) δ 135.6, 118.3, 101.2, 90.1, 59.3, 46.4, 41.8, 0.3; IR (film) 2218 cm-1. MS (ESI) 182.1365 
(182.1360 calcd for C10H19NSi, M + H
+). 
 
 
 
 
(Z)-methyl N-methyl-N'-tosyl-N-(3-(trimethylsilyl)prop-2-yn-1-yl)carbamimidothioate (3-
9). The intermediate compound was prepared using the general procedure reported by Looper.22 
A Schlenk flask equipped with a stirbar was flame-dried under vacuum, and was evacuated and 
backfilled with nitrogen. The flask was charged with tetrakis(triphenylphosphine)palladium(0) and 
1,3-dimethylbarbituric acid (2.96 g, 19 mmol), and was then evacuated and backfilled with 
nitrogen. A solution of 3-8 (2.29 g, 12.7 mmol) and dichloromethane (63 mL) was added through 
a rubber septum. The resulting solution was stirred overnight (16 h) at rt, and had turned to a 
golden yellow color. The crude material was dissolved in ether (70 mL) and transferred to a 
separatory funnel. A solution of saturated bicarbonate (25 mL) was added to the separatory funnel. 
The layers were separated, and the organic layer was extracted. The organic layer was washed with 
a solution of saturated becarbonate (2 x 25 mL), then washed with 1 M HCl (3 x 25 mL). The 
combined acidic aqueous layers were basified with potassium carbonate, then transferred to a 
separatory funnel. Dichloromethane (25 mL) was added to the separatory funnel. The layers were 
separated, and the organic layer was extracted. The aqueous layer was washed with 
dichloromethane (2 x 25 mL). The combined organic extracts were dried over anhydrous sodium 
sulfate, filtered, and gently concentrated in vacuo. The obtained product N-methyl-3-
(trimethylsilyl)prop-2-yn-1-amine was directly carried on to the next step of the reaction.  
A flame-dried bomb flask equipped with a stirbar was cooled under a stream of N2, and charged 
with dimethyl tosylcarbonimidodithioate (2.89 g, 10.5 mmol), N-methyl-3-(trimethylsilyl)prop-2-
yn-1-amine (1.78 g, 12.6 mmol), and toluene (12 mL). The resulting solution was stirred for 2.5 h 
at 100 °C, then dissolved in diethyl ether (50 mL) and transferred to a separatory funnel. 1 M HCl 
(5 mL) was added to the separatory funnel. The layers were separated, and the organic layer was 
dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude material was 
purified by flash chromatography on silica gel to afford 3.41 g (88% over both steps) of the title 
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compound as a white solid. The material contained ca. 6% of substrate tosylcarbonimidodithioate. 
mp = 66–70 °C. 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 8 Hz, 2 H), 7.25 (d, J = 8 Hz, 2 H), 
4.36 (s, 2 H), 3.25 (s, 3 H), 2.58 (s, 3 H), 2.40 (s, 3 H), 0.17 (s, 9 H); 13C NMR (125 MHz, CDCl3) 
δ 167.3, 142.0, 141.7, 129.3, 126.3, 98.1, 91.4, 43.5, 38.6, 21.6, 18.1, -0.1; IR (film) 2178, 1527 
cm-1. MS (ESI) 369.1123 (369.1121 calcd for C16H24N2O2S2Si, M + H
+). 
 
 
 
 
(E)-N-(amino(methyl(3-(trimethylsilyl)prop-2-yn-1-yl)amino)methylene)-4-
methylbenzenesulfonamide (3-1). A flame-dried bomb flask equipped with a stirbar was cooled 
under a stream of N2, and charged with 3-9 (1.38 g, 3.7 mmol), mercury (II) oxide (1.22 g, 5.6 
mmol), ammonia (37 mL, 2 M solution in ethanol), and triethylamine (2.35 mL, 16.8 mmol). The 
resulting reaction mixture was stirred at rt overnight (15 h), during which the mixture changed 
from bright orange to gray with hints of orange. The reaction mixture was filtered through a plug 
of celite, and the celite was washed with dichloromethane (200 mL). The filtrate was concentrated 
in vacuo to afford the crude product, which was purified by flash chromatography on silica gel to 
afford 907 mg (72%) of the title compound as an off white powder solid: mp = 136–137 °C. 1H 
NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8 Hz, 2 H), 7.23 (d, J = 8 Hz, 2 H), 6.35 (s, br, 2 H), 4.22 
(s, 2 H), 3.00 (s, 3 H), 2.39 (s, 3 H), 0.15 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 156.0, 142.1, 
141.2, 129.3, 126.2, 99.1, 90.8, 40.0, 34.7, 21.6, -0.1; IR (film) 3415, 3330, 2178, 1629, 1544, 
1495 cm-1. MS (ESI) 338.1354 (338.1353 calcd for C15H23N3O2SSi, M + H
+). 
 
 
 
 
 
 
 
 
54 
 
General Procedure for the Pd-Catalyzed Synthesis of 2-Aminoimidazoles. A flame-dried 
Schlenk tube equipped with a stir bar was cooled under vacuum and charged with 3-1 (1.0 equiv), 
RuPhos (0.08 equiv), and lithium tert-butoxide (2.4 equiv). The appropriate aryl triflate (2.0 equiv) 
was added. The flask was evacuated and purged with N2. A pre-stirred solution of palladium (II) 
acetate (0.04 equiv) in trifluorotoluene (0.9 mg/mL) was added via syringe and the tube was heated 
to 100 °C and stirred overnight (~16 h). The mixture was cooled to rt and H2O (10 mL/mmol 
substrate) and ethyl acetate (25 mL/mmol substrate) were added. The layers were separated and 
the aqueous layer was extracted with ethyl acetate (25 mL/mmol substrate). The organic layers 
were combined and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel.  
 
 
 
 
N-(4-(benzo[d][1,3]dioxol-5-yl(trimethylsilyl)methyl)-1-methyl-1H-imidazol-2-yl)-4-
methylbenzenesulfonamide (3-3). The general procedure was employed for the coupling of 3-1 
(51 mg, 0.15 mmol) and benzo[d][1,3]dioxol-5-yl trifluoromethanesulfonate (31 μL, 0.18 mmol), 
using a catalyst composed of Pd(OAc)2(1.3 mg, 0.006 mmol) and RuPhos (5.6 mg, 0.012 mmol). 
This procedure afforded 55 mg (80%) of the title compound as a light orange powder solid: mp = 
90–93 °C. 1H NMR (500 MHz, CDCl3) δ 9.70 (s, br, 1 H), 7.75 (d, J = 8.5 Hz, 2 H), 7.19 (d, J = 
8 Hz, 2 H), 6.73–6.71 (m, 1 H), 6.50–6.48 (m, 2 H), 6.13 (s, 1 H), 5.94 (s, 2 H), 3.32 (s, 3 H), 3.22 
(s, 1 H), 2.37 (s, 3 H), 0.05 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 148.0, 146.8, 145.9, 141.7, 
132.9, 129.3, 126.3, 126.0, 121.0, 111.3, 108.6, 108.4, 101.2, 34.6, 31.7, 21.6, -2.0 (one carbon 
signal is missing due to incidental equivalence); IR (film) 3293, 1619, 1585, 1485 cm-1. MS (ESI) 
458.1569 (458.1564 calcd for C22H27N3O4SSi, M + H
+).  
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N-(4-((4-methoxyphenyl)(trimethylsilyl)methyl)-1-methyl-1H-imidazol-2-yl)-4-
methylbenzenesulfonamide (3-4). The general procedure was employed for the coupling of 3-1 
(51 mg, 0.15 mmol) and 4-methoxyphenyl trifluoromethanesulfonate (33 μL, 0.18 mmol), using a 
catalyst composed of Pd(OAc)2 (1.3 mg, 0.006 mmol) and RuPhos (5.6 mg, 0.012 mmol). This 
procedure afforded 57 mg (85%) of the title compound as a pale yellow oil: 1H NMR (500 MHz, 
CDCl3) δ 9.76 (s, br, 1 H), 7.75 (d, J = 8.5, 2 H), 7.17 (d, J = 8 Hz, 2 H), 6.95 (d, J = 8.5 Hz, 2 H),                                                                                                                                                                                                                       
6.80 (d, J = 8.5 Hz, 2 H), 6.13 (s, 1 H), 3.78 (s, 3 H), 3.31 (s, 3 H), 3.28 (s, 1 H), 2.36 (s, 3 H), 
0.03 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 157.9, 146.7, 141.8, 141.6, 131.1, 129.2, 129.0, 
126.7, 126.0, 114.2, 111.1, 55.4, 33.9, 31.7, 21.5, 2.1; IR (film) 3289, 1616, 1581, 1508 cm-1. MS 
(ESI) 444.1784 (444.1772 calcd for C22H29N3O3SSi, M + H
+). 
 
 
4-methyl-N-(1-methyl-4-(p-tolyl(trimethylsilyl)methyl)-1H-imidazol-2-
yl)benzenesulfonamide (3-5). The general procedure was employed for the coupling of 3-1 (51 
mg, 0.15 mmol) and p-tolyl trifluoromethanesulfonate (54 μL, 0.30 mmol), using a catalyst 
composed of Pd(OAc)2 (1.3 mg, 0.006 mmol) and RuPhos (5.6 mg, 0.012 mmol). This procedure 
afforded 53 mg (82%) of the title compound as an off-white powder solid: mp = 172–173 °C 1H 
NMR (500 MHz, CDCl3) δ 9.73 (s, br, 1 H), 7.74 (d, J = 8 Hz, 2 H), 7.16 (d, J = 8 Hz, 2 H), 7.06 
(d, J = 7.5 Hz, 2 H), 6.91 (d, J = 8 Hz, 2 H), 6.13 (s, 1 H), 3.30 (s, 3 H), 3.27 (s, 1 H), 2.36 (s, 3 
H), 2.30 (s, 3 H), 0.03 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 146.9, 141.9, 141.8, 136.1, 135.7, 
129.6, 129.4, 128.0, 126.6, 126.1, 111.3, 34.7, 31.8, 21.7, 21.2, -2.0; IR (film) 3288, 1618, 1581 
cm-1. MS (ESI) 428.1825 (428.1823 calcd for C22H29N3O2SSi, M + H
+). 
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4-methyl-N-(1-methyl-4-(o-tolyl(trimethylsilyl)methyl)-1H-imidazol-2-
yl)benzenesulfonamide (3-6): The general procedure was employed for the coupling of 3-1 (51 
mg, 0.15 mmol) and o-tolyl trifluoromethanesulfonate (53 μL, 0.30 mmol), using a catalyst 
composed of Pd(OAc)2 (1.3 mg, 0.006 mmol) and RuPhos (5.6 mg, 0.012 mmol). This procedure 
afforded 50 mg (78%) of the title compound as an off-white powder solid: mp = 188–190 °C 1H 
NMR (500 MHz, CDCl3) δ 9.65 (s, br, 1 H), 9.74 (d, J = 8.5, 2 H), 7.19–7.09 (m, 5 H), 7.01 (d, J 
= 8 Hz, 1 H), 6.08 (s, 1 H), 3.54 (s, 1 H), 3.29 (s, 3 H), 2.36 (s, 3 H), 2.27 (s, 3 H), 0.06 (s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 146.6, 141.9, 141.5, 137.5, 135.7, 131.3, 129.4, 127.9, 126.6, 
126.5, 126.3, 126.1, 111.1, 31.8, 30.1, 21.8, 20.9, -1.7; IR (film) 3292, 1616, 1580, 1483 cm-1. MS 
(ESI) 428.1824 (428.1823 calcd for C22H29N3O2SSi, M + H
+). 
 
 
 
N-(4-((4-benzoylphenyl)(trimethylsilyl)methyl)-1-methyl-1H-imidazol-2-yl)-4-
methylbenzenesulfonamide (3-7). The general procedure was employed for the coupling of 3-1 
(51 mg, 0.15 mmol) and 4-benzoylphenyl trifluoromethanesulfonate (99.1 mg, 0.30 mmol), using 
a catalyst composed of Pd(OAc)2 (1.3 mg, 0.006 mmol) and RuPhos (5.6 mg, 0.012 mmol). This 
procedure afforded 74 mg (95%) of the title compound as an off-white powder solid: mp = 206–
208 °C 1H NMR (700 MHz, CDCl3) δ 9.98 (s, br, 1 H), 7.77 (t, J = 8.4 Hz, 4 H), 7.69 (d, J = 8.4 
Hz, 2 H), 7.58 (t, J = 7.7 Hz, 1 H), 7.48 (t, J = 7.7 Hz, 2 H), 7.16 (d, J = 7.7 Hz, 2 H), 7.13 (d, J = 
8.4 Hz, 2 H) 6.24 (s, 1 H), 3.58 (s, 3 H), 2.34 (s, 3 H), 0.04 (s, 9 H);13C NMR (175 MHz, CDCl3) 
δ 196.4, 146.7, 144.8, 141.9, 141.7, 137.9, 135.2, 132.5, 130.7, 130.1,1 129.3, 128.5, 127.8, 126.0, 
125.5, 111.8, 35.3, 31.8, 21.6, -2.2; IR (film) 3290, 1619, 1581 cm-1. MS (ESI) 518.1938 (518.1928 
calcd for C28H31N3O3SSi, M + H
+). 
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Conversion of 3-1 to Preclathridine A 
 
 
 
N-(4-(benzo[d][1,3]dioxol-5-ylmethyl)-1-methyl-1H-imidazol-2-yl)-4-
methylbenzenesulfonamide (3-10). A flame-dried Schlenk tube equipped with a stir bar was 
cooled under vacuum and charged with 3-1 (51 mg, 0.15 mmol), RuPhos (5.6 mg, 0.012 mmol), 
and lithium tert-butoxide (29 mg, 0.36 mmol). Benzo[d][1,3]dioxol-5-yl 
trifluoromethanesulfonate (64 μL, 0.30 mmol) was added. The flask was evacuated and purged 
with N2. A pre-stirred solution of palladium (II) acetate (1.3 mg, 0.006 mmol) in trifluorotoluene 
(1.5 mL) was added via syringe and the tube was heated to 100 °C and stirred overnight (~16 h). 
4 M HCl in dioxane (2 mL) was added, and reaction continued stirring at 100 °C for 25 min. The 
mixture was cooled to rt and saturated sodium barcarbonate was added to the reaction mixture (4 
mL). The mixture was transferred to a separatory funnel, and ethyl acetate was added (30 mL). 
The layers were separated, and the organic layer was extracted. The aqueous layer was washed 
with ethyl acetate (2 x 30 mL). The organic layers were combined and concentrated in vacuo. The 
crude material was purified by flash chromatography on silica gel to afford 34 mg (59%) of the 
title compound as an off-white solid: mp = 193–194 °C 1H NMR (500 MHz, CDCl3) δ 9.95 (s, br, 
1 H), 7.78 (d, J = 8.5 Hz, 2 H), 7.19 (d, J = 8 Hz, 2 H), 6.72 (d, J = 8.5 Hz, 1 H), 6.61 (d, J = 6.5 
Hz, 2 H), 5.97 (s, 1 H), 5.94 (s, 2 H), 3.66 (s, 2 H), 3.27 (s, 3 H), 2.37 (s, 3 H); 13C NMR (125 
MHz, CDCl3) δ 148.2, 147.3, 146.9, 141.8, 141.7, 130.0, 129.3, 126.0, 125.0, 121.9, 112.1, 109.2, 
108.6, 101.3, 31.7, 31.2, 21.6; IR (film) 3287, 1581, 1488 cm-1. MS (ESI) 386.1172 (386.1169 
calcd for C19H19N3O4S, M + H
+). 
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Preclathridine A (3-11): A Schlenk tube equipped with a stir bar was flame-dried under vacuum. 
The flask was then evacuated and backfilled with nitrogen. The vessel was charged with an excess 
of lithium wire (100 mg), naphthalene (55.5 mg, 0.43 mmol), and THF (1 mL). The reaction 
mixture was allowed to stir at rt for 30 minutes, during which the mixture turned from clear, to 
dark green, to a deep red. The flask was then purged with nitrogen and cooled to -78 °C. Compound 
3-10 (33 mg, 0.072 mmol) was allowed to stir in THF (2 mL) at 60 °C for 30 min. The solution of 
compound 3-10 in THF was quickly transferred to the cooled vessel containing the mixture of 
lithium, naphthalene, and THF. No color change was observed. The reaction mixture was allowed 
to stir at -78 °C for 1.5 h. The flask was then allowed to warm to rt. During this period, the reaction 
was slowly quenched with a solution of saturated sodium bicarbonate (10 mL). The mixture was 
transferred to a separatory funnel. Dichloromethane (30 mL) and a solution of saturated sodium 
bicarbonate (15 mL) were added to the separatory funnel. The layers were separated, and the 
organic layer was extracted. The aqueous layer was washed with dichloromethane (3 x 30 mL). 
The organic layers were combined, dried, filtered, and concentrated in vacuo. The crude material 
was purified by flash chromatography on silica gel to afford 12 mg (74%) of the title compound 
as a light brown solid. The compound matches characterization data found in the literature.57 1H 
NMR (500 MHz, CDCl3) δ 7.27 (s, br, 2 H), 6.73 (d, J = 8.5 Hz, 1 H), 6.68 (d, J = 6 Hz, 2 H), 6.00 
(s, 1 H), 5.92 (s, 2 H), 3.68 (s, 2 H), 3.53 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 147.9, 147.2, 
146.7, 129.6, 127.0, 121.9, 112.7, 109.1, 108.5, 101.0, 32.8, 30.9; IR (film) 3104, 1669, 1489 cm-
1. MS (ESI) 232.1089 (232.1081 calcd for C12H13N3O2, M + H
+). 
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